

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 4 APR 07 STN is raising the limits on saved answers
NEWS 5 APR 24 CA/CAPLUS now has more comprehensive patent assignee
information
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent
assignment/reassignment information
NEWS 7 APR 28 CAS patent authority coverage expanded
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9 APR 28 Limits doubled for structure searching in CAS
REGISTRY
NEWS 10 MAY 08 STN Express, Version 8.4, now available
NEWS 11 MAY 11 STN on the Web enhanced
NEWS 12 MAY 11 BEILSTEIN substance information now available on
STN Easy
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased
limits for exact sequence match searches and
introduction of free HIT display format
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal
status data
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in
records back to 1992
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching
enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges

and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 19:34:34 ON 16 JUN 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 19:34:43 ON 16 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3
DICTIONARY FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10568344\Struc 3.str



```

ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18
chain bonds :
1-7
ring bonds :
1-2  1-5  2-3  2-18  3-4  3-6  4-5  6-8  6-12  7-13  7-17  8-9  8-18  9-10  10-11
11-12  13-14  14-15  15-16  16-17
exact/norm bonds :
1-2  1-5  1-7  2-3  2-18  3-4  3-6  4-5  8-18
normalized bonds :
6-8  6-12  7-13  7-17  8-9  9-10  10-11  11-12  13-14  14-15  15-16  16-17

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 19:35:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3677 TO ITERATE

54.4% PROCESSED 2000 ITERATIONS

9 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 69903 TO 77177

PROJECTED ANSWERS: 86 TO 574

L2 9 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 19:35:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 73297 TO ITERATE

100.0% PROCESSED 73297 ITERATIONS

765 ANSWERS

SEARCH TIME: 00.00.02

L3 765 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 19:35:17 ON 16 JUN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2009 VOL 150 ISS 25
 FILE LAST UPDATED: 15 Jun 2009 (20090615/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l3
 L4 45 L3
 => d ibib abs hitstr 1-45

L4 ANSWER 1 OF 45 CAPLUS COPYRIGHT 2009 ACS ON STN
 ACCESSION NUMBER: 2009:555826 CAPLUS
 DOCUMENT NUMBER: 150:526744
 TITLE: Complexes with tridentate ligands
 INVENTOR(S): Walters, Robert W.; Tsai, Jui-Yi; MacKenzie, Peter
 Borden; Beers, Scott
 USA
 PATENT ASSIGNEE(S):
 SOURCE: U.S. Pat. Appl. Publ., 143pp., Cont.-in-part of U.S.
 Ser. No. 973,265.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


US 20090115322	A1	20090507	US 2008-240584	20080929
US 20090092854	A1	20090409	US 2007-973265	20071004
WO 2009046266	A1	20090409	WO 2008-US78697	20081003

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-973265 A2 20071004
US 2008-240584 A 20080929

GI




AB The present invention relates to organic light emitting devices (OLEDs), and more specifically to phosphorescent organic materials used in such devices. More specifically, the present invention relates to emissive phosphorescent material I [$M = 2\text{nd}$ or 3rd row transition metal; L - ancillary ligand; ring A = 8- to 12-membered bicyclic ring having 3 - 6 heteratoms, 11- to 18-membered tricyclic having 3 - 6 heteratoms, 11- to 14-membered fused bicyclic, or 14- to 18-membered fused tetracyclic; RA = alkyl, alkenyl, alkynyl, aralkyl, O-R', N(R')₂, SR', C(O)R', C(O)NR', CN, CF₃, NO₂, SO₂R', SO₂R', Si(R')₃, halo, aryl or heteroaryl; a = 0 - 4; ring B = 5- or 6-membered ring, 8- to 12-membered bicyclic, 11- to 18-membered tricyclic, 11- to 18-membered fused tricyclic, or 14- to 18-membered fused tetracyclic] which comprise at least one tridentate ligand bound to a metal center, wherein at least one of the bonds to the tridentate ligand is a C-metal bond.

IT 1141494-1P
RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(complexes with tridentate ligands)

RN 1141494-94-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L4 ANSWER 2 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:487913 CAPLUS

DOCUMENT NUMBER: 150:472908

TITLE: Transition metal cyclometalated complexes with chelating bidentate N-heterocyclic carbene-heterocycle ligands as light-emitting materials for organic light-emitting devices (OLEDs)

INVENTOR(S): Molt, Oliver; Lennartz, Christian; Fuchs, Evelyn; Kahle, Klaus; Langer, Nicolle; Schildknecht, Christian; Rudolph, Jens; Wagenblast, Gerhard; Watanabe, Soichi

PATENT ASSIGNEE(S): Basf Se, Germany

SOURCE: PCT Int. Appl., 70pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009050281	A1	20090423	WO 2008-EP64064	20081017
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,				

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

EP 2007-118675

A 20071017


EP 2008-153303

A 20080326

OTHER SOURCE(S):

MARPAT 150:472908

GI



AB Transition metal complexes I [1, (NHC)MLmZn, M = Group IB, IIB metal, transition metal, lanthanide, preferably M = Ir, Os, Pt; L = mono- or bidentate neutral ligand; Z = mono- or dianionic ligand; X = C, N, preferably X = N, R1 absent; when X = C, R1 = F, CN, C1-20 alkoxy, alkylthio, C6-30 aryloxy, arylthio, C6-30 (hetero)aryl; R2 = organyl, A, D, E, G, J, K, Q, T = N, CH, C-organyl, two adjacent ring atoms may form a 3-6-membered cycle; x > 1; m, n = 0, ≥1], useful as stable and efficient light-emitting materials for manufacturing of organic light-emitting devices, were prepared by metalation of the azolium carbene precursors [NHC-H]+Y- (2·Y, same A, D, E, G, J, K, Q, T, R1, R2; Y = halide, pseudohalide, BF4-, BPh2-, PF6-, AsF6-, SbF6-), preferably in one-pot process with a metal complex and ligands L and HZ, preferably by reaction of [NHC-H]+Y- with [Ir2(μ-Cl)2(η4-1,5-cod)2]. In an example, 11.0 mmol of the ligand iodide precursor, 1-methyl-1,2,4-triazolo[4,3-f]phenanthridinium iodide (2a·I; X = N, R1 absent, R2 = Me, A = D = E = G = J = K = Q = T = CH) was reacted with 5.5 mmol of Ag2O in 200 mL of MeOH for 16 h at 20° under argon, giving 94% of the silver carbene (NHC)AgI (3a), which was reacted with [Ir2(μ-Cl)2(η4-1,5-cod)2] to give the mer-(NHC)3Ir (1a, X = N, R1 absent, R2 = Me, A = D = E = J = K = Q = T = CH, G = C; x = 3, m = n = 0) with 75% yield. In another example, the complex 1a exhibited blue emission at 448, 481 nm upon excitation at 325 nm by HeCd laser; the light-emitting layer made with 1a as an active component exhibited electroluminescence at 452, 479 nm, efficiency of 13.4 cd/A, quantum yield of 7.2% and maximum brightness of 1300 cd/m2.


IT 888725-36-8

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses)
 (preparation and electroluminescence of iridium cyclometalated annelated azolyliene N-heterocyclic carbene chelate complexes, light-emitting

layers and devices)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:422572 CAPLUS

DOCUMENT NUMBER: 150:434745

TITLE: A light emitting device using a phosphor comprising complexes with tridentate ligands

INVENTOR(S): Walters, Robert W.; Tsai, Jui-Yi; MacKenzie, Peter Borden; Beers, Scott

PATENT ASSIGNEE(S): Entire Interest, USA

SOURCE: U.S. Pat. Appl. Publ., 134pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090092854	A1	20090409	US 2007-973265	20071004
US 20090115322	A1	20090507	US 2008-240584	20080929
WO 2009046266	A1	20090409	WO 2008-US78697	20081003
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				

TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 PRIORITY APPLN. INFO.: US 2007-973265 A2 20071004
 US 2008-240584 A 20080929

AB A light emitting device using a phosphor comprising complexes with
 tridentate ligands is described, where the emissive phosphorescent
 material comprises at least one tridentate ligand bound to a metal center,
 and where at least one of the bonds to the tridentate ligand is a
 carbon-metal bond.


IT 1141494-61-2 1141494-83-8 1141494-84-9
 1141494-94-1
 RL: TEM (Technical or engineered material use); USES (Uses)
 (light emitting devices using phosphor comprising complexes with
 tridentate ligands)

RN 1141494-61-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 1141494-83-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 1141494-84-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 1141494-94-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



L4 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:422571 CAPLUS
 DOCUMENT NUMBER: 150:434744

TITLE: A light emitting device using a phosphor comprising complexes with tridentate ligands
 INVENTOR(S): Walters, Robert W.; Tsai, Jui-Yi; MacKenzie, Peter Borden; Beers, Scott A.
 PATENT ASSIGNEE(S): Universal Display Corporation, USA
 SOURCE: PCT Int. Appl., 187pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009046266	A1	20090409	WO 2008-US78697	20081003
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090092854	A1	20090409	US 2007-973265	20071004
US 20090115322	A1	20090507	US 2008-240584	20080929
PRIORITY APPLN. INFO.:			US 2007-973265	A 20071004
			US 2008-240584	A 20080929
AB	A light emitting device using a phosphor comprising complexes with tridentate ligands is described, where the emissive phosphorescent material comprises at least one tridentate ligand bound to a metal center, and where at least one of the bonds to the tridentate ligand is a carbon-metal bond.			
IT	1141494-61-2 1141494-83-8 1141494-84-9 1141494-94-1 RL: TEM (Technical or engineered material use); USES (Uses) (light emitting devices using phosphor comprising complexes with tridentate ligands)			
RN	1141494-61-2 CAPLUS			
CN	INDEX NAME NOT YET ASSIGNED			
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
RN	1141494-83-8 CAPLUS			
CN	INDEX NAME NOT YET ASSIGNED			
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
RN	1141494-84-9 CAPLUS			
CN	INDEX NAME NOT YET ASSIGNED			
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
RN	1141494-94-1 CAPLUS			
CN	INDEX NAME NOT YET ASSIGNED			



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:418723 CAPLUS

DOCUMENT NUMBER: 150:409823

TITLE: Organic electroluminescence devices having prescribed light-emitting layers and carbene compound layers

INVENTOR(S): Sato, Yu; Kinoshita, Masaji; Tobiyo, Manabu

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 124pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 2009076509	A	20090409	JP 2007-241625	20070918
PRIORITY APPLN. INFO.:				JP 2007-241625	20070918
AB	The devices have carbene compound-containing layers between light-emitting (LE) layers and anodes (preferably adjacent to the LE layers) for reduced drive voltage and improved electroluminescent efficiency. The LE layers contain ≥ 1 hole transport material (A) and ≥ 1 electron transport material (B), where A and/or B are light-emitting materials, and the concentration of B decreases from cathodes toward anodes.				
IT	913611-59-3				
RL:	TEM (Technical or engineered material use); USES (Uses) (hole transport layer; organic EL devices having predetd. light-emitting layers and carbene compound layers for reduced drive voltage and improved electroluminescent efficiency)				
RN	913611-59-3 CAPLUS				
CN	Rhodium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-				

, (OC-6-22)- (CA INDEX NAME)



L4 ANSWER 6 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:332832 CAPLUS

DOCUMENT NUMBER: 150:362860

TITLE: Metal complexes, organic electroluminescent elements containing them with high emission efficiency and durability, and displays and illumination apparatus using them

INVENTOR(S): Ikemizu, Hiroshi; Nishizeki, Masato; Oshiyama, Tomohiro; Kato, Eisaku; Kita, Hiroshi

PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 98pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent


LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
JP 2009057505	A	20090319	JP 2007-227500	20070903
PRIORITY APPLN. INFO.:			JP 2007-227500	20070903
GI				



AB The metal complexes are depicted as I ($R_1 = \text{H, substituent}$; $n_1 = 1-4$; $R_4 = \text{cyclic hydrocarbon group, heterocyclic group}$; $Z_1 = 5\text{- or }6\text{-membered cyclic or heterocyclic group}$; $A = \text{CR}_2, \text{N}$; $R_2 = \text{H, substituent}$; $B = \text{CR}_3, \text{N}$; $R_3 = \text{H, substituent}$; $X_1L_1X_2 = \text{bidentate ligand}$; $X_1, 2 = \text{H, N, O}$; $L_1 = \text{atomic group}$; $m_1 = 1-3$; $m_2 = 0-2$; $m_1 + m_2 = 2, 3$; $M_1 = \text{Group 8-10 metal}$), thus giving LED with high color purity and low power consumption.

IT 1133240-84-2P


RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(dopant; metal complexes for organic LED with high emission efficiency and durability)


RN 1133240-84-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 2-A




IT 1133240-83-1 1133240-85-3 1133240-88-6

1133240-89-7 1133240-90-0

RL: TEM (Technical or engineered material use); USES (Uses)
(dopant; metal complexes for organic LED with high emission efficiency and durability)



RN 1133240-83-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED






RN 1133240-85-3 CAPLUS



CN INDEX NAME NOT YET ASSIGNED



RN 1133240-88-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1133240-90-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 1133240-94-4 1133240-97-7 1133241-00-5
 1133241-03-8 1133241-06-1 1133241-12-9
 1133241-16-3 1133241-19-6 1133241-21-0
 1133241-23-2


RL: TEM (Technical or engineered material use); USES (Uses)
 (emission layer; metal complexes for organic LED with high emission
 efficiency and durability)

RN 1133240-94-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1133240-93-3
 CMF C55 H51 Ir N6
 CCI CCS



CM 2
 CRN 953414-49-8
 CMF C32 H22 N2



RN 1133240-97-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CM 1
 CRN 1133240-96-6
 CMF C38 H26 N2




CM 2



CRN 1133240-95-5

CMF C56 H53 Ir N6

CCI CCS

PAGE 1-A






RN 1133241-00-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



CM 1

CRN 1133240-99-9
CMF C38 H24 N2 O



CM 2


CRN 1133240-98-8
CMF C60 H49 Ir N6
CCI CCS



RN 1133241-03-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1133241-02-7
CMF C56 H34 N2 O2




CM 2

CRN 1133241-01-6
 CMF C60 H55 Ir N6
 CCI CCS

PAGE 1-A




PAGE 2-A



RN 1133241-06-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1133241-05-0
CMF C39 H26 N2 O





CM 2

CRN 1133241-04-9
CMF C69 H63 Ir N6
CCI CCS

PAGE 1-A




PAGE 2-A



RN 1133241-12-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1133241-11-8
CMF C32 H26 N2




CM 2

CRN 1133241-10-7


CMF C63 H61 Ir N6

CCI CCS

PAGE 1-A



PAGE 2-A





RN 1133241-16-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1133241-15-2
CMF C63 H59 Ir N6
CCI CCS

PAGE 1-A






CM 2
 CRN 934972-67-5
 CMF C30 H20 N4



RN 1133241-19-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED
 CM 1
 CRN 1133241-18-5
 CMF C56 H53 Ir N6
 CCI CCS

PAGE 1-A




PAGE 2-A



CM 2

CRN 1133241-17-4


CMF C36 H24 N4



CM 3

CRN 1133240-96-6

CMF C38 H26 N2



RN 1133241-21-0 CAPLUS



CN Iridium, bis[1,1'-biphenyl]-3,4-diyl[3-(2,4,6-trimethylphenyl)-1H-benzimidazol-1-yl-2(3H)-ylidene]][4-[1-(4-ethenyl-2-methylphenyl)-1H-imidazol-2-yl-κN3][1,1'-biphenyl]-3-yl-κC]-, polymer with 9,9'-(5-ethenyl-1,3-phenylene)bis[9H-carbazole] (CA INDEX NAME)


CM 1

CRN 1133241-20-9

CMF C80 H65 Ir N6

CCI CCS






CM 2

CRN 953414-49-8

CMF C32 H22 N2



RN 1133241-23-2 CAPLUS



CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1133241-22-1

CMF C80 H59 Ir N6

CCI CCS






CM 2

CRN 1133240-96-6

CMF C38 H26 N2



L4 ANSWER 7 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:195407 CAPLUS

DOCUMENT NUMBER: 150:329946

TITLE: Reactivity of $[\text{Ru}_4(\mu\text{-H})_4(\text{CO})_{12}]$ with N-heterocyclic carbenes

AUTHOR(S): Cabeza, Javier A.; del Rio, Ignacio; Fernandez-Colinas, Jose M.; Perez-Carreno, Enrique; Sanchez-Vega, M. Gabriela; Vazquez-Garcia, Digna

CORPORATE SOURCE: Departamento de Quimica Organica e Inorganica-IUQOEM, Universidad de Oviedo-CSIC, Oviedo, E-33071, Spain

SOURCE: Organometallics (2009), 28(6), 1832-1837

CODEN: ORGND7; ISSN: 0276-7333

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The tetraruthenium tetrahydrido cluster compound $[\text{Ru}_4(\mu\text{-H})_4(\text{CO})_{12}]$ (1) reacts at room temperature with N-heterocyclic imidazolylidene carbenes 1,3-R1R2Im to give the carbonyl substitution products $[\text{Ru}_4(\mu\text{-H})_4(\text{CO})_{11}(\text{R1R2Im})]$ (2-5; R1, R2: Me, Me; Ph, Me; Ph, Ph; mesityl, mesityl). In solution, compds. 2-5 are fluxional in the NMR time scale and display the same pattern of $\nu(\text{CO})$ IR absorptions. DFT calcns. have shown that the Cs arrangement of the Ru_4H_4 cluster core of these clusters is 0.2-1.7 kcal mol⁻¹ more stable than the D2d cluster core, the smallest difference corresponding to the clusters with the very bulky 1,3-dimesitylimidazolin-2-ylidene ligand. Two conformers with Cs Ru_4H_4

cluster core have been found by x-ray crystallog. in the crystals of compound 3. The thermal stability of compds. 2-5 has also been studied. While the di-Me derivative 2 is stable in refluxing toluene for 3 h, the dimesityl derivative 5 slowly decomp. in solution at room temperature. Two isostructural heptanuclear derivs.,

$[\text{Ru}^{\text{II}}_7(\mu_3\text{-H})(\mu_4\text{-CO})(\mu\text{-CO})_2(\text{CO})_{14}\{\mu\text{-}(\eta^1\text{-}\eta^6\text{-C}_6\text{H}_4)\text{RIm}\}]$ (6, 7; R = Me, Ph), which contain a quadruply bridging CO ligand and an orthometalated Ph ring that is addnl. coordinated as an $\eta^6\text{-arene}$ ligand, are the major products of the thermolysis of compds. 3 and 4 in toluene at reflux temperature


IT 1132683-47-6P



RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, structure and stability of tetra- and heptaruthenium cluster 2-imidazolyldiene carbonyl tetrahydride carbene complexes)



RN 1132683-47-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A










PAGE 3-C



PAGE 4-B



REFERENCE COUNT:

46

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:116764 CAPLUS

DOCUMENT NUMBER: 150:179607

TITLE: Organic electroluminescent element with high
light-emission efficiency and excellent durability
employing multiple hole-transporting light-emitting
materials with graded compositions

INVENTOR(S): Okada, Hisashi; Tobise, Manabu; Kinoshita, Masaru
PATENT ASSIGNEE(S): Japan

SOURCE: U.S. Pat. Appl. Publ., 29pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090026940	A1	20090129	US 2008-178457	20080723
JP 2009032987	A	20090212	JP 2007-196673	20070727
PRIORITY APPLN. INFO.:			JP 2007-196673	A 20070727


AB An organic electroluminescent element is discussed including an organic layer including at least a light-emitting layer between a pair of electrodes, where the light-emitting layer comprises at least two hole transporting materials and an electron transporting host material, with at least one of the hole transporting materials being a hole transporting light-emitting material, and a total concentration of the at least two hole transporting materials in the light-emitting layer decreases from an anode side toward a cathode side.

IT 888725-36-8

RL: TEM (Technical or engineered material use); USES (Uses)
(light-emitting layer containing; organic electroluminescent element with high light-emission efficiency and excellent durability employing multiple hole-transporting light-emitting materials with graded compns.)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:116719 CAPLUS

DOCUMENT NUMBER: 150:155945

TITLE: Organic electroluminescent elements employing a hole transporting light-emitting material with a graded concentration

INVENTOR(S): Okada, Hisashi; Tobise, Manabu; Kinoshita, Masaru

PATENT ASSIGNEE(S): Japan

SOURCE: U.S. Pat. Appl. Publ., 27pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090026938	A1	20090129	US 2008-178445	20080723
JP 2009032990	A	20090212	JP 2007-196676	20070727
PRIORITY APPLN. INFO.:			JP 2007-196676	A 20070727


AB Organic electroluminescent elements are described including an organic layer including a light-emitting layer disposed between a pair of electrodes, where the light-emitting layer contains at least one hole transporting light-emitting material and at least one electron-transporting host material, and a concentration of the hole transporting light-emitting material in the light-emitting layer decreases from an anode side toward a cathode side.

IT 888725-36-8

RL: TEM (Technical or engineered material use); USES (Uses) (hole-transporting phosphorescent material; organic electroluminescent elements employing hole transporting light-emitting material with graded concentration)



RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:114549 CAPLUS
 DOCUMENT NUMBER: 150:179594
 TITLE: Organic electroluminescence (EL) devices with high
 luminous efficiency and suppressed dark spot, and
 display devices and lamps having them
 INVENTOR(S): Yasukawa, Noriko; Kato, Eisaku
 PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 105pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2009021336	A	20090129	JP 2007-182063	20070711
PRIORITY APPLN. INFO.:			JP 2007-182063	20070711
OTHER SOURCE(S):	MARPAT	150:179594		
GI				





AB The EL devices include anodes, luminescent layers containing host compds. and metal complexes, electron transport layers, and cathodes, wherein the luminescent layers contain metal complexes of I (X4 = N, C; Z = hydrocarbon ring, heterocyclic ring; X3, Y = C, N; A = atomic groups forming 5 to 6-membered hydrocarbon or heterocyclic ring with X3C; B = CR1:CR2, N:CR2, CR1:N, N:N; R1, R2 = H, substituent; X1L1X2 = bidentate ligand; X1, X2 = C, N, O; L1 = atomic group forming bidentate ligand with X1 and X2; m1 = 1, 2, 3; m2 = 0, 1, 2; m1 + m2 = 2, 3; M1 = Group VIII metal), and the electron transport layers contain II [n = 1, 2; Ar = arylene, heteroarylene; R3, R4 = H, aryl; X1-3 = :CR, :N; at least one of X1-3 is :N; R = H, substituent; Cz = (un)substituted carbazoyl]. The devices can prevent crystallization of organic layers.

IT 1100761-23-6

RL: TEM (Technical or engineered material use); USES (Uses)
(dopant, luminescent layer; organic EL devices with high luminous efficiency and suppressed dark spot for display devices and lamps)

RN 1100761-23-6 CAPLUS

CN Iridium, [(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[1-(2,4,6-trimethylphenyl)-1H-imidazol-2-yl-kN3]phenyl-kC]- (CA INDEX NAME)



L4 ANSWER 11 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:114548 CAPLUS

DOCUMENT NUMBER: 150:179593

TITLE: Organic electroluminescent (EL) devices with high luminous efficiency and suppressed dark spot, and display devices and lamps having them
Yasukawa, Noriko; Kato, Eisaku
PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan



SOURCE: Jpn. Kokai Tokkyo Koho, 98pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2009021335	A	20090129	JP 2007-182062	20070711
PRIORITY APPLN. INFO.:			JP 2007-182062	20070711
OTHER SOURCE(S):	MARPAT 150:179593			
GI				



AB The EL devices include anodes, luminescent layers containing host compds. and metal complexes, and cathodes, wherein the luminescent layers contain metal complexes of I (X4 = N, C; Z = hydrocarbon ring, heterocyclic ring; X3, Y = C, N; A = atomic groups forming 5 to 6-membered hydrocarbon or heterocyclic ring with X3C; B = CR1:CR2, N:CR2, CR1:N, N:N; R1, R2 = H, substituent; X1L1X2 = bidentate ligand; X1, X2 = C, N, O; L1 = atomic group forming bidentate ligand with X1 and X2; m1 = 1, 2, 3; m2 = 0, 1, 2; m1 + m2 = 2, 3; M1 = Group VIII metal) and Ar4Ar5N(p-C6H4-xRxx)mAr2NAr1Ar3(p-C6H4-yRyy)nAr6Ar7 (Ar1 = aryl; Ar2, Ar3 = arylene; Ar4-7 = aryl; Rx, Ry = substituent; x, y = 0-4; m, n = 0-3; Ar2 and Ar3, Ar4 and Ar5, and/or Ar6 and Ar7 are connected through direct bonding, O, S, or alkylene). The metal complexes (dopants) and host compds. will not interact with each other, thus cause no crystallization in organic layers.


IT 1100761-23-6

RL: TEM (Technical or engineered material use); USES (Uses)
 (dopant; organic EL devices with high luminous efficiency and suppressed dark spot for displays and lamps)


RN 1100761-23-6 CAPLUS

CN Iridium, [(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[1-(2,4,6-trimethylphenyl)-1H-imidazol-2-yl-κN3]phenyl-κC]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 12 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:86345 CAPLUS

DOCUMENT NUMBER: 150:155890

TITLE: Organic electroluminescence device showing improved light efficiency, luminescence lifetime, uniform brightness, and suppressed dark spot formation, and its use in display and illumination apparatus

INVENTOR(S): Yasukawa, Noriko; Kato, Eisaku



PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 112pp.

DOCUMENT TYPE: CODEN: JKXXAF
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: Japanese
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2009016719	A	20090122	JP 2007-179521	20070709

PRIORITY APPLN. INFO.:
 GI JP 2007-179521 20070709



AB The title organic electroluminescence device contains a metal complex compound represented by I [X1, X2 = C, N, O; X3 = C, N; X3, X4, Y = C, N; Z = hydrocarbon ring, heterocycle ring; A = atom group for forming 5- to 6-member hydrocarbon or heterocycle ring; B = -C(R01):C(R02)-, -N:C(R02)-, -C(R01):N-, -N:N-; R01, R02 = H, substituent; L1 = atom group for forming ligand; m1 = 1, 2, 3; m2 = 0, 1, 2; m1+m2 = 2 or 3; M1 = group 8 to 10 metal] in an electroluminescence layer and a compound represented by II [A1-4 = substituent; L = -Ar5-(-L2-Ar6-)n1-; Ar5, Ar6 = arylene; L2 = single bond, connection group; n1 = 0, 1; n2, n3, n4, n5 = 0-5] in a pos. hole transport layer.

IT 1100761-23-6


RL: MOA (Modifier or additive use); USES (Uses)
 (electroluminescence dopant material; organic electroluminescence device)

showing improved light efficiency, luminescence lifetime, uniform brightness, and suppressed dark spot formation, and its use in display and illumination apparatus)


RN 1100761-23-6 CAPLUS

CN Iridium, [(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[1-(2,4,6-trimethylphenyl)-1H-imidazol-2-yl-kN3]phenyl-kC]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



L4 ANSWER 13 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:86314 CAPLUS
 DOCUMENT NUMBER: 150:155889

TITLE:	Organic electroluminescence device showing high light efficiency, long luminous lifetime, improved storage stability, and suppressed dark spot formation, and its use in display apparatus and illumination apparatus
INVENTOR(S):	Yasukawa, Noriko; Kato, Eisaku
PATENT ASSIGNEE(S):	Konica Minolta Holdings, Inc., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 89pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2009016718	A	20090122	JP 2007-179520	20070709
PRIORITY APPLN. INFO.:			JP 2007-179520	20070709
GI				




AB The title organic electroluminescence device contains a metal complex compound represented by I [$X1, X2 = C, N, O; X3 = C, N; X3, X4, Y = C, N; Z =$ hydrocarbon ring, heterocycle ring; A = atom group for forming 5- to 6-member hydrocarbon or heterocycle ring; B = $-C(R01):C(R02)-, -N:C(R02)-, -C(R01)-N-, -N:N-; R01, R02 = H, substituent; L1 =$ atom group form forming ligand; $m1 = 1, 2, 3; m2 = 0, 1, 2; m1+m2 = 2$ or 3; $M1 =$ group 8 to 10 metal] and a compound represented by II [A = alkyl, alkoxy, aryl, heteroarvl; $Ar1-4 =$ arvl; Rx, Ry, Rz = substituent; $x, z = 0-4; y = 0-3$]

in an electroluminescence layer.
 IT 1100761-23-6
 RL: MOA (Modifier or additive use); USES (Uses)
 (electroluminescence dopant material; organic electroluminescence device
 showing high light efficiency, long luminous lifetime, improved storage
 stability, and suppressed dark spot formation, and its use in display
 apparatus and illumination apparatus)
 RN 1100761-23-6 CAPLUS
 CN Iridium, [(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-
 phenylene]bis[2-[1-(2,4,6-trimethylphenyl)-1H-imidazol-2-yl-
 κN3]phenyl-κC]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 14 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:20278 CAPLUS

DOCUMENT NUMBER: 150:132601

TITLE: Organic light-emitting diodes comprising at least one disilyl compound selected from disilylcarbazoles, disilyldibenzofurans, disilyldibenzothiophenes, disilyldibenzophospholes, disilyldibenzothiophene S-oxides and disilyldibenzothiophene S,S-dioxides

INVENTOR(S): Langer, Nicolle; Kahle, Klaus; Lennartz, Christian; Molt, Oliver; Fuchs, Evelyn; Rudolph, Jens; Schildknecht, Christian; Watanabe, Soichi; Wagenblast, Gerhard

PATENT ASSIGNEE(S): BASF SE, Germany

SOURCE: PCT Int. Appl., 102pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009003919	A1	20090108	WO 2008-EP58207	20080626
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
PRIORITY APPLN. INFO.:			EP 2007-111824	A 20070705
			EP 2008-153306	A 20080326
AB	<p>Organic light-emitting diodes comprising an anode and a cathode and a light-emitting layer arranged between the anode and the cathode, and optionally ≥ 1 addnl. layer are described in which the light-emitting layer and/or the addnl. layer(s) comprises ≥ 1 compound selected from disilylcarbazoles, disilyldibenzofurans, disilyldibenzothiophenes, disilyldibenzophospholes, disilyldibenzothiophene S-oxides, and disilyldibenzothiophene S,S-dioxides. Light-emitting layers comprising ≥ 1 of the aforementioned compds., the use of the compds. as matrix materials, hole/exciton blocker materials, electron/exciton blocker materials, hole injection materials, electron injection materials, hole conductor materials and/or electron conductor materials, and devices selected from the group consisting of stationary visual display units, mobile visual units and illumination units comprising ≥ 1 of the organic light-emitting diodes are also described.</p>			
IT	<p>888725-36-8</p> <p>RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)</p> <p>(organic light-emitting diodes comprising at least one disilyl compound)</p>			

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1502745 CAPLUS

DOCUMENT NUMBER: 150:67325

TITLE: Organic electroluminescent elements and electroluminescent materials

INVENTOR(S): Fujimura, Osamu; Fukunaga, Kenji; Honma, Takashi; Machida, Toshikazu

PATENT ASSIGNEE(S): UBE Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 46pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008153088	A1	20081218	WO 2008-JP60734	20080612
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2007-156265 A 20070613

JP 2008-2869


A 20080110

AB An object of this invention is to produce a phosphorescent organic electroluminescent element which can realize an electroluminescent peak in a deep blue region of not more than 440 nm which is important for completing a full-color display. The object can be attained by an organic electroluminescent element comprising a pair of electrodes, a luminescent layer or a plurality of thin organic compound layers including a luminescent layer between the pair of electrodes, characterized in that a phosphorescent electroluminescent peak appears at a wavelength of not more than 440 nm and further characterized in that the maximum phosphorescent electroluminescent peak appears in a deep blue region at a wavelength of not more than 440 nm, and the luminescent color is such that, in a CIE color system, y-coordinate is less than 0.180.

IT 895556-02-2
 RL: TEM (Technical or engineered material use); USES (Uses)
 (phosphorescent organic electroluminescent elements for full-color displays)

RN 895556-02-2 CAPLUS

CN Iridium, tris[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1334493 CAPLUS

DOCUMENT NUMBER: 149:534395

TITLE: Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups as matrix and blocker components of organic light-emitting devices (OLEDs)
 INVENTOR(S): Moonen, Nicolle; Kahle, Klaus; Lennartz, Christian; Schildknecht, Christian; Nord, Simon; Molt, Oliver; Fuchs, Evelyn; Rudolph, Jens; Wagenblast, Gerhard

PATENT ASSIGNEE(S): BASF SE, Germany

SOURCE: PCT Int. Appl., 80pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----
WO 2008132085	A1	20081106	WO 2008-EP54801
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		20080421
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
PRIORITY APPLN. INFO.:			EP 2007-107055
OTHER SOURCE(S):	MARPAT 149:534395		A 20070426
AB	<p>Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups, [(R2oR3pC12H8-o-pXN)nLmSiR14-m (1; C12H8XN = 10-phenothiazinyl S-oxide, X = SO; 10-phenothiazinyl S,S-dioxide, X = SO2; R2, R3 = alkyl, (hetero)aryl, amino, hydroxy, alkoxy, aryloxy, arylcarbonyloxy, acyl, amido, ester, thiocarboxylate, carbonylamino, silyl; R1 = H, alkyl, aryl, 4-carbazol-9-ylphenyl; m = 1-4, preferably 2-4; n = 1,2; o, p = 0-4, preferably o, p = 0; L = bridging group, preferably L = (un)substituted phenylene, heterocyclodiy], useful as electron-conducting/blocker or electron and hole conducting/blocker materials, as components for light-emitting layers in combination with a triplet emitter metal complex, were prepared by a multistep procedure, comprising N-alkylation of (un)substituted phenothiazine by a spacer derivative X-L-Y to give a phenothiazine derivs. (R2oR3pC12H8-o-pXN)nLY (2, same R, L; X = S, Y = halo), followed by reaction with halo- or alkoxysilanes R1mSiY14-m (6; Y1 = halo, alkoxy) and oxidation of the phenothiazine moiety into S-oxide or S,S-dioxide. In an example, Grignard reaction of 10-(4-bromophenyl)phenothiazine with Me2SiCl2 gave bis-thiazine silane, (SC12H8N-1,4-C6H4)2SiMe2, which gave the compound of the invention, (O2SC12H8N-1,4-C6H4)2SiMe2 (1a) upon oxidation with 70% m-chloroperbenzoic acid for 20 h at 20°. In another example, OLED having iridium tris[1-methyl-3-(4-trifluoromethylphenyl)benzimidazole] complex as a dopant to a light-emitting matrix composed from the compound 1a, exhibited electroluminescence at 455 nm with 6.0 cd/A current efficiency, 5.4% quantum yield and 400 cd/m2 light d. Preparation of iridium cyclometalated N-arylbenzimidazole carbene complexes as phosphorescent materials is also described.</p>		
IT	<p>888725-36-8 RL: TEM (Technical or engineered material use); USES (Uses) (preparation of silyl phenothiazine oxides and dioxides as electron-, hole-transporting and matrix materials for organic light-emitting devices comprising cyclometalated iridium carbene complexes)</p>		
RN	888725-36-8 CAPLUS		
CN	<p>Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)</p>		



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1149160 CAPLUS

DOCUMENT NUMBER: 149:543892

TITLE: Controlling the radiative rate of deep-blue electrophosphorescent organometallic complexes by singlet-triplet gap engineering

AUTHOR(S): Haneder, Stephan; Da Como, Enrico; Feldmann, Jochen; Lupton, John M.; Lennartz, Christian; Erk, Peter; Fuchs, Evelyn; Molt, Oliver; Muenster, Ingo; Schildknecht, Christian; Wagenblast, Gerhard

CORPORATE SOURCE: Photonics and Optoelectronics Group, Department of Physics and CeNS, Ludwig-Maximilians-Universitaet, Munich, 80799, Germany

SOURCE: Advanced Materials (Weinheim, Germany) (2008), 20(17), 3325-3330

CODEN: ADVMEW; ISSN: 0935-9648

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The phosphorescence radiative rate of electroluminescent metal complexes is controlled by the singlet-triplet splitting (AEST). The figure shows how the chemical tailoring of AEST influences the radiative rate in a new class of deep-blue emitting complexes. This approach holds promise for the preparation of efficient deep-blue OLEDs (see inset) for solid state lighting applications.


IT 888725-36-8

RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(controlling the radiative rate of deep-blue electrophosphorescent organometallic complexes by singlet-triplet gap engineering)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1029003 CAPLUS

DOCUMENT NUMBER: 149:378875

TITLE: C-H Bond Activation through σ -Bond Metathesis and Agostic Interactions: Deactivation Pathway of a Grubbs Second-Generation Catalyst

AUTHOR(S): Mathew, Jomon; Koga, Nobuaki; Suresh, Cherumuttathu H.
CORPORATE SOURCE: Computational Modeling and Simulation Section, National Institute for Interdisciplinary Science and Technology, CSIR, Trivandrum, Kerala, India

SOURCE: Organometallics (2008), 27(18), 4666-4670
CODEN: ORGND7; ISSN: 0276-7333

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A mechanistic study was carried out to explore the structural and energetic features leading to the decomposition pathways of a Grubbs 2nd-generation olefin metathesis catalyst using d. functional theory. The active form of the catalyst 2 has an inherent tendency to undergo intramol. reactions, as the highly electron-deficient Ru center is in close proximity to the C-H bonds of the N-substituents. The theor. results strongly suggest that the deactivation pathway initiates with the C-H activation rather than pericyclic cyclization suggested for the related Grubbs-Hoveyda catalyst system by Blechert et al. Complex 2 passes through five transition states, viz., (i) formation of an agostic complex through the activation of a C-H bond of the N-heterocyclic carbene (NHC)-Ph ring; (ii) C-H σ -bond metathesis with a carbene moiety to form a benzyl complex; (iii) two-step rotational transformations of the benzyl unit; and (iv) carbene-arene bond formation to yield the 1st product, 3. The last step is the rate-determining step, with the highest activation barrier of 28.6 kcal/mol, while the activation energy for steps (i), (ii), and (iii) are 13.6, 26.7, and 18.8 kcal/mol, resp. The transformation of the rigid carbene unit to a flexible benzyl unit facilitates the rotational transformations in step (iii) and the subsequent C-C bond formation in step (iv). The η^6 -coordination of Ph ring in 3 changes to η^2 to produce a less strained complex, and the

C-H activation of the 2nd NHC-Ph ring occurs easily with this transformation, leading to a C-H agostic complex through a transition state with the activation barrier of 28.3 kcal/mol. The agostic interaction breaks up in the next step, leading to the Ru-C bond formation and the reductive elimination of HCl to the 2nd product, 4. The flexibility of all three Ph rings through their single bond connectivity plays a major role in the deactivation process of 2, as it leads to C-H agostic interactions with the Ru center. Therefore, the deactivation can be controlled by designing NHCs with rigid substituents, which may not undergo agostic interactions.

IT 1059139-80-8 1059139-82-0 1059139-86-4


1059139-87-5

RL: PRP (Properties)

(calculated optimized geometry and energy; mechanism of deactivation pathway of a Grubbs second-generation olefin metathesis catalyst via C-H bond activation and agostic interactions using DFT)


RN 1059139-80-8 CAPLUS

CN Ruthenium, dichloro[1,3-dihydro-1-(phenyl-κC2,κH2)-3-phenyl-1H-benzimidazol-2-ylidene-κC2](phenylmethylene)-, (OC-6-52)- (CA INDEX NAME)




RN 1059139-82-0 CAPLUS

CN Ruthenium, dichloro[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene](phenylmethyl-κC,κH)-, (OC-6-52)- (CA INDEX NAME)




RN 1059139-86-4 CAPLUS

CN Ruthenium, dichloro[1,3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene]-1,2-phenylene[(phenyl-κC)methyl-κC]-, (OC-6-32)- (CA INDEX NAME)



RN 1059139-87-5 CAPLUS

CN Ruthenium, dichloro[1,3-dihydro-1-phenyl-3-[2-[(phenyl-κC)methyl-κC]phenyl-κC2]-2H-benzimidazol-2-ylidene]-, (OC-6-43)- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:773582 CAPLUS

DOCUMENT NUMBER: 149:91175

TITLE: Organic electroluminescent devices including no optical defect and high luminance and efficiency
INVENTOR(S): Iwakuma, Toshihiro; Watanabe, Masami; Okuda, Fumio; Nishimura, Kazuki; Hosokawa, Chishio

PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2008147424	A	20080626	JP 2006-332946	20061211
PRIORITY APPLN. INFO.:			JP 2006-332946	20061211
OTHER SOURCE(S):	MARPAT 149:91175			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The devices contain, in the layers adjacent to emitting layers, metal complexes I-IV [M = metal; R1 = H, alk(en)yl, alkynyl, (hetero)aryl, etc.; R2, R3, R8, R11, R12 = H, alkyl, aralkyl, CN, CF3, halo, etc.; J = R, CN, CF3, CO2R, etc. (R = H, halo, alk(en)yl, etc.); XY = chiral ligand, auxiliary ligand; e = 0-4; m, n \geq 1; m + n = the maximum coordination number for M]. The layers adjacent to the emitting layers may be hole-, electron-, and/or exciton-blocking layers. The devices show long service life.

IT 913636-78-9
 RL: TEM (Technical or engineered material use); USES (Uses)
 (exciton-blocking layers; organic electroluminescent devices including no optical defect and high luminance and efficiency)

RN 913636-78-9 CAPLUS


CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, (OC-6-22)- (CA INDEX NAME)




ACCESSION NUMBER: 2008:773530 CAPLUS
 DOCUMENT NUMBER: 149:91173
 TITLE: Organic electroluminescent devices free from image defects and showing high efficiency at low drive voltage
 INVENTOR(S): Iwakuma, Toshihiro; Watanabe, Masami; Okuda, Fumio; Nishimura, Kazuki; Hosokawa, Chishio
 PATENT ASSIGNEE(S): Idemitsu Kosan Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 18pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008147400	A	20080626	JP 2006-332516	20061208
PRIORITY APPLN. INFO.: OTHER SOURCE(S):	MARPAT 149:91173		JP 2006-332516	20061208

GI



AB The devices have, in hole-injection and/or -transport layers, metal complexes represented by I and/or II [R1-R7 = H, CN, nitro, halo, C1-20 alkyl(oxy), amino, etc.; M = Ir, Rh, Pt, Pd; n = 1-3] and preferably (Cz)cAr4bAr3Ar1aAr2 [Cz = (C18-60 aryl)carbazolyl, azacarbazolyl, etc.; Ar1, Ar2 = C6-60 aryl, C3-60 heterocycle; Ar3 = C6-60 aromatic or C3-60 heterocyclic group; Ar4 = benzene, thiophene, triazole, or (spiro)fluorene residue] in emitting layers.
 IT 895556-06-6
 RL: TEM (Technical or engineered material use); USES (Uses) (hole-injecting layers; organic electroluminescent devices free from defects and showing high efficiency at low drive voltage)
 RN 895556-06-6 CAPLUS
 CN Iridium, tris[[5-(1-methylethyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:531767 CAPLUS

DOCUMENT NUMBER: 150:398687

TITLE: Discovery and synthesis of a new bis(thiourea)-Pd pincer guided by ESI-MS/MS

AUTHOR(S): Rui, Li; Wei, Chen; Shi, Jianyou; Chen, Lijuan; Chen, Yingchun; Ding, Lisheng; Wei, Yuquan

CORPORATE SOURCE: State Key Lab. Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, Peop. Rep. China

SOURCE: Journal of Mass Spectrometry (2008), 43(4), 542-546

CODEN: JMSPFJ; ISSN: 1076-5174

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The fission mechanisms of thioureas and their corresponding Pd complexes under electrospray ionization (ESI) conditions were investigated. A new bis(thiourea)palladium pincer and a series of hybrid (thiourea and carbene)palladium pincers and bis (carbene)palladium pincer were observed in ESI-MS expts. The new bis(thiourea)palladium pincer was synthesized and its catalytic activity in the Suzuki coupling reaction forming biaryls was compared with the bis(thiourea)-Pd0 complex. E.g., coupling of 3-O₂NC₆H₄Br with PhB(OH)₂ gave 99% m-PhC₆H₄NO₂ with either of these palladium catalysts.

IT 1138479-16-9P



RL: CAT (Catalyst use); PRP (Properties); SPN (Synthetic preparation);

PREP (Preparation); USES (Uses)

(mol. structure; discovery and preparation of a new bis(thiourea)palladium pincer guided by ESI-MS/MS and catalytic activity of this and similar complexes in Suzuki coupling reaction)

RN 1138479-16-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:381102 CAPLUS
 DOCUMENT NUMBER: 148:366850
 TITLE: Organic light emitting diode display with extended lifetime
 INVENTOR(S): Schildknecht, Christian; Fuchs, Evelyn; Moonen, Nicolle; Kahle, Klaus; Lennartz, Christian; Molt, Oliver; Wagenblast, Gerhard; Rudolph, Jens
 PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008034758	A2	20080327	WO 2007-EP59648	20070913
WO 2008034758	A3	20080710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 KR 2009051266 A 20090521 KR 2009-706991 20090406
 PRIORITY APPLN. INFO.: EP 2006-121077 A 20060921
 EP 2007-111816 A 20070705
 WO 2007-EP59648 W 20070913

OTHER SOURCE(S): MARPAT 148:366850


AB The present invention relates to an organic light-emitting diode (OLED) which has a light-emitting layer C which contains at least one hole-conducting material and at least one phosphorescence emitter, mixts. containing at least one carbene complex in combination with at least one hole-conducting material or in combination with at least one phosphorescence emitter, and the use of mixts. containing at least one hole-conducting material and at least one phosphorescence emitter as a light-emitting layer in OLEDs for extending the lifetime of the light-emitting layer. The organic light-emitting diode according to the invention can have in at least one of the layers of the organic light-emitting diode, preferably in the hole-blocking layer and/or the electron-blocking layer and/or the light-emitting layer, in addition to the hole-conducting material and the emitter, at least one compound selected from disilylcarbazoles, disilyldibenzofurans, disilyldibenzothiophenes, disilyldibenzophospholes, disilyldibenzothiophene-S-oxides and disilyldibenzothiophene-S,S-dioxides.

IT 888725-36-8

RL: TEM (Technical or engineered material use); USES (Uses)
 (organic light emitting diode display with extended lifetime)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-
 (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:378150 CAPLUS

DOCUMENT NUMBER: 148:366829

TITLE: Organic electroluminescence element showing improved
 blue phosphorescent light emitting efficiency, service
 life, and chromaticity


INVENTOR(S): Suzuri, Yoshiyuki; Nakata, Aki; Naito, Mitsuyoshi;
 Kita, Hiroshi

PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: PCT Int. Appl., 81pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008035571	A1	20080327	WO 2007-JP67391	20070906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: JP 2006-254127 A 20060920
 OTHER SOURCE(S): MARPAT 148:366829
 GI



I

AB Disclosed is an organic electroluminescence element which is improved in efficiency of emitting blue phosphorescent light, service life and chromaticity. Also disclosed is an organic electroluminescence element which can extract white light including the blue phosphorescent light. The organic electroluminescence elements are characterized by comprising an anode, a light-emitting layer unit having multiple light-emitting layers and a cathode, wherein each of at least two of the multiple light-emitting layers contains a phosphorescent compound represented by the general formula I (R1 = substituent; Z = nonmetal atoms for forming 5- to 7-membered ring; n1 = 0-5; B1-5 = C, N, O, S; at least one of B1-5 is N; M1 = group 8 metal, group 9 metal, group 10 metal; X1, X2 = C, N, O; L1 = atoms together with X1 and X2 for forming ligand; m1 = 1, 2, 3; m2 = 0, 1, 2; m1+m2 = 2 or 3).

IT 895556-02-2
 RL: MOA (Modifier or additive use); USES (Uses)
 (organic electroluminescence element showing improved blue phosphorescent
 light emitting efficiency, service life, and chromaticity)
 RN 895556-02-2 CAPLUS
 CN Iridium, tris[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]-
 (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:87809 CAPLUS

DOCUMENT NUMBER: 148:285328

TITLE: Computational study of C-C activation of
 1,3-dimesitylimidazol-2-ylidene (IMes) at ruthenium:
 the role of ligand bulk in accessing reactive
 intermediates

AUTHOR(S): Diggle, Richard A.; Macgregor, Stuart A.; Whittlesey,
 Michael K.

CORPORATE SOURCE: School of Engineering and Physical Sciences,
 Heriot-Watt University, Edinburgh, EH14 4AS, UK

SOURCE: Organometallics (2008), 27(4), 617-625

CODEN: ORGND7; ISSN: 0276-7333


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB D. functional theory calcns. have been employed to model phosphine
 substitution in Ru(PPh3)3(CO)(H)2 to form Ru(IMes)(PPh3)2(CO)(H)2 (lmono)
 and Ru(IMes)2(PPh3)(CO)(H)2 (lbis), as well as the novel C(aryl)-C(sp3)
 intramol. bond activation of the IMes ligand in lbis. The computed ligand
 exchange energies show that lbis is unstable with respect to displacement
 of IMes by PPh3 and will thus re-form lmono over time. PPh3/IMes
 substitution also leads to a significant labilization of the PPh3 ligand
 trans to hydride, a result of increasing steric encumbrance upon the
 introduction of the bulky IMes ligands. The energetics of intramol. C-C
 and C-H activation have been computed for both 16e Ru(IMes)n(PPh3)3-n(CO)
 and 14e Ru(IMes)n(PPh3)2-n(CO) species (n = 1 or 2) and indicate that the
 introduction of a second IMes ligand does not significantly promote the
 actual C-C activation step. Instead the need to have two IMes ligands
 present in the metal coordination sphere before C-C activation can occur
 is linked to the promotion of PPh3 loss in lbis, which makes the formation


- of unsatd. species such as Ru(IMes)₂(CO) particularly accessible.
- IT 434318-96-4 1008533-71-8 1008533-73-0
1008533-74-1 1008533-75-2
- RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
(steric effects in carbon-hydrogen and carbon-carbon bond activation of dimesityl imidazolydene ruthenium carbene hydride complexes)
- RN 434318-96-4 CAPLUS
- CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]]hydrobis(triphenylphosphine)-, (OC-6-14)-(9CI) (CA INDEX NAME)



- RN 1008533-71-8 CAPLUS
- CN Ruthenium, carbonyl[1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene][(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]]methyl-, (SP-5-54)- (CA INDEX NAME)




- RN 1008533-73-0 CAPLUS
- CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]]methyl(triphenylphosphine)-, (SP-5-53)-(CA INDEX NAME)




RN 1008533-74-1 CAPLUS

CN Ruthenium, carbonyl[1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene][3,5-dimethyl-1,2-phenylene][3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]methyl(triphenylphosphine)-, (OC-6-65)- (CA INDEX NAME)




RN 1008533-75-2 CAPLUS


CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]methylbis(triphenylphosphine)-, (OC-6-53)- (CA INDEX NAME)




IT 1008533-79-6 1008533-88-7 1008797-88-3
 RL: FMU (Formation, unclassified); PRP (Properties); RCT (Reactant); FORM
 (Formation, nonpreparative); RACT (Reactant or reagent)
 (steric effects in carbon-hydrogen and carbon-carbon bond activation of
 dimesityl imidazolydene ruthenium carbene hydride complexes)
 RN 1008533-79-6 CAPLUS
 CN Ruthenium, carbonyl(dihydrogen-κH1,κH2) [(3,5-dimethyl-1,2-
 phenylene) [3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-
 ylidene]]methyl(triphenylphosphine)-, (PB-7-24-13566)- (CA INDEX NAME)



RN 1008533-88-7 CAPLUS
 CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene) [3-(2,4,6-trimethylphenyl)-
 1H-imidazol-1-yl-2(3H)-ylidene]]hydro(triphenylphosphine)-, (SP-5-14)-
 (CA INDEX NAME)



RN 1008797-88-3 CAPLUS
 CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]methyl(triphenylphosphine)-, (SP-5-35)-(CA INDEX NAME)



REFERENCE COUNT: 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 25 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:1176628 CAPLUS
 DOCUMENT NUMBER: 147:448934
 TITLE: Heteroleptic cyclometalated transition metal-carbene complexes containing at least two differently substituted N-heterocyclic carbene ligands and their use in organic light-emitting diodes (OLEDs)
 INVENTOR(S): Fuchs, Evelyn; Egen, Martina; Kahle, Klaus; Lennartz, Christian; Molt, Oliver; Nord, Simon; Kowalsky, Wolfgang; Schildknecht, Christian; Johannes, Hans-Hermann
 PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 88pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007/115970	A1	20071018	WO 2007-EP53213	20070403
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2007779	A1	20081231	EP 2007-727684	20070403
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
US 20090096367	A1	20090416	US 2008-296112	20081006
KR 2009005349	A	20090113	KR 2008-726664	20081030
PRIORITY APPLN. INFO.:			EP 2006-112228	A 20060405
			WO 2007-EP53213	W 20070403
OTHER SOURCE(S):	MARPAT 147:448934			
AB	<p>Cyclometalated transition metal complexes, preferably iridium complexes [M(L)n(L1)m], (1; M = Ir, Co, Rh, Ni, Pd, Pt, Fe, Ru, Os, Cr, Mo, W, Tc, Re, Cu, Au, preferably M = Ir, Pt, Rh, Os; n+m ≥ 2), containing sym.- and asym. substituted ligands L and L1, resp., having the structure of R3sQ2CR2:CR1XN(Y1)CQ1(Y2)Y3r [Q1 = C, P, N, O, S, Si, preferably Q1 = P, N, O, S; Q2 = bond, C-, N-, P-, O-, S-; r, s = 2-0, according to the valence of Q1, Q2; X = bond, silylene, C2-10 alkylene, (hetero)arylene, alkenediyl, alkynediyl, imino, phosphinidene, boryl, O, S, SO, SO2, CO, CO2, OCO; Y1, Y2 = H, organyl, Y1-Y2 = bridge forming 5-7-membered ring; Y3 = H, organyl for asym. L1, Y3 = R3sQ2CR2:CR1XN(Y1) with same meanings for sym. L; R1, R2 = H, organyl, R1-R2 = bridge forming (un)saturated 5-7-membered ring; R3 = H, organyl], useful as phosphorescent substances for doping of light-emitting OLED layers, having enhanced tunability by variation of ligands and high electroluminescence efficiency, were prepared by stepwise complexation/metalation of the corresponding ligands L and L1 with metal precursors and examined for their luminescence spectra and efficiency. In an example, iridium carbene intermediate [(COD)ClIr:C(NPh)2(1,2-C6H4)] [1a, C(NPh)2(1,2-C6H4) = 1,3-diphenylbenzimidazol-2-ylidene] was prepared by reaction of 22.5 mmol of [Ir2(μ-Cl)2(COD)2] with 45 mmol of 1,3-diphenylbenzimidazol-2-ylidene (L) generated from 45 mmol of 1,3-diphenylbenzimidazolium tetrafluoroborate by 45 mmol of potassium hexamethyldisilazide in 250 mL of toluene with 49% yield. The intermediate 1a was then reacted with AgBF4 and 3 equiv of 1-(4-cyanophenyl)-3-methylimidazol-2-ylidene (L1), generated from the corresponding imidazolium salt, giving the cyclometalated product, according to invention, [[1-(C6H4-κC2)-3-Ph-benzimidazol-2-ylidene][1-(4-NCC6H3-κC2)-3-Me-imidazol-2-ylidene]2Ir] (1b) with 34% yield. In another example, a polymethylmethacrylate film doped with 2 wt% of the complex 1b exhibited electroluminescence at 450 nm with quantum yield of 78%.</p>			
IT	<p>952311-89-6P RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP</p>			

(Preparation); PROC (Process); USES (Uses)
 (electroluminescence; preparation and electroluminescence of iridium
 heteroleptic cyclometalated unsym. substituted N-heterocyclic carbene
 complexes as dopants for high-efficient organic light-emitting devices)

RN 952311-89-6 CAPLUS

CN Iridium, bis[(5-cyano-1,2-phenylene) (3-methyl-1H-imidazol-1-yl-2(3H)-
 ylidene)][(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-
 (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1102763 CAPLUS

DOCUMENT NUMBER: 148:11327

TITLE: Cyclometalated and Alkoxyphenyl-Substituted Palladium
 Imidazolin-2-ylidene Complexes. Synthetic, Structural,
 and Catalytic Studies

AUTHOR(S): Stylianides, Neoklis; Danopoulos, Andreas A.; Pugh,
 David; Hancock, Fred; Zanotti-Gerosa, Antonio
 CORPORATE SOURCE: School of Chemistry, University of Southampton,
 Southampton, SO17 1BJ, UK

SOURCE: Organometallics (2007), 26(23), 5627-5635
 CODEN: ORGND7; ISSN: 0276-7333

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:11327

AB 1,3-Diarylimidazolinium salts, having one unsubstituted ortho-position of
 the aryl ring, [1,3-Ar2C3H5N2]X [3a-h; Ar = 2-MeC6H4, 2-iPrC6H4,
 2-MeOC6H4, 4-MeOC6H4, 2,4-(MeO)2C6H3, 2-iPrOC6H4, 4-iPrOC6H4,
 2,4,6-(MeO)3C6H2] were prepared by heterocyclization of the corresponding
 N,N'-diaryl-1,2-ethanediamines with tri-Et orthoformate. The salts 3a-g
 undergo deprotonation and cyclopalladation with Pd(tmeda)Me2 affording


cis-bis-carbene complexes (6), mono- and new type of "pincer" bis-ortho-metallated species (9, 8) and Pd(0) complex trans-[L2Pd] (7, HL = proligands 3). The activities of the new bis-acetato-bridged palladium ortho-metallated dimer (4) and methylpalladium mono-metallated bis-carbene [(1,3-Ar2C3H4-κC2)[1-Ar-3-(4-MeOC6H3-κC2')]C3H4N2-κC2]Pd(Me)] (9d, Ar = 4-MeOC6H4) in the Heck reaction of aryl halides were compared. At higher temps. the complexes 9d and its 2,4-dimethoxyphenyl analog (9e) show low activity in the coupling of aryl chlorides.

IT 957476-14-1P 957476-15-2P

RL: CAT (Catalyst use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(crystal structure; preparation, structure and catalytic activity of palladium ortho-metallated 1,3-diaryl-2-imidazolidinylidene carbene complexes)


RN 957476-14-1 CAPLUS

CN Palladium, [1,3-bis(2,4-dimethoxyphenyl)-2-imidazolidinylidene]methyl[(5-methoxy-1,2-phenylene)[3-(4-methoxyphenyl)-1-imidazolidinyl-2-ylidene]]-, (SP-4-3)- (CA INDEX NAME)



RN 957476-15-2 CAPLUS

CN Palladium, [1,3-bis(2,4-dimethoxyphenyl)-2-imidazolidinylidene]methyl[(3,5-dimethoxy-1,2-phenylene)[3-(2,4-dimethoxyphenyl)-1-imidazolidinyl-2-ylidene]]-, (SP-4-3)- (CA INDEX NAME)





IT 957476-10-7P 957766-89-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure; preparation, structure and catalytic activity of

palladium ortho-metalated 1,3-diaryl-2-imidazolidinylidene carbene complexes)

RN 957476-10-7 CAPLUS

CN Palladium, [1,3-bis[2-(1-methylethyl)phenyl]-2-imidazolidinylidene]chloro[6-(1-methylethyl)-1,2-phenylene][3-[3-(1-methylethyl)phenyl]-1-imidazolidinyl-2-ylidene]]-, (SP-4-4)- (CA INDEX NAME)



RN 957766-89-1 CAPLUS


CN Palladium, bis[μ-(acetato-κO:κO')]bis[(3-methyl-1,2-phenylene)[3-(2-methylphenyl)-1-imidazolidinyl-2-ylidene]]di-, stereoisomer, compd. with methylbenzene (2:3) (CA INDEX NAME)

CM 1

CRN 957476-09-4

CMF C38 H40 N4 O4 Pd2

CCI CCS



CM 2

CRN 108-88-3

CMF C7 H8



IT 957476-09-4P


RL: CAT (Catalyst use); PRP (Properties); SPN (Synthetic preparation);

PREP (Preparation); USES (Uses)

(mol. structure; preparation, structure and catalytic activity of palladium
ortho-metalated 1,3-diaryl-2-imidazolidinylidene carbene complexes)

RN 957476-09-4 CAPLUS

CN Palladium, bis[μ-(acetato-κO:κO')]bis[(3-methyl-1,2-
phenylene)[3-(2-methylphenyl)-1-imidazolidinyl-2-ylidene]]di-,
stereoisomer (CA INDEX NAME)



REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:816691 CAPLUS

DOCUMENT NUMBER: 147:177347

TITLE: Phosphor dopant host material for organic electroluminescent device to improve light efficiency and extend service life, its use in display and illumination apparatus

INVENTOR(S): Otsu, Shinya; Kato, Eisaku

PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 42pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007189001	A	20070726	JP 2006-4679	20060112
PRIORITY APPLN. INFO.:			JP 2006-4679	20060112
OTHER SOURCE(S):		MARPAT 147:177347		
GI				



AB In an organic electroluminescent device comprising a luminescent layer sandwiched between an anode and a cathode, the device contains a compound represented by I (R1-6 = H, substituent like aromatic group, heterocycle group, carbazole group, azacarbazole group, and diphenylamino group; X1-5 = C, N) as a host material for a phosphor dopant, as an electron blocking material or as a hole blocking material. The luminescent layer contains a phosphor dopant emitting ≤ 485 nm light and having an ionization potential of ≤ 5.5 eV.


IT 943988-43-0

RL: MOA (Modifier or additive use); USES (Uses)

(phosphor dopant; phosphor dopant host material for organic electroluminescent device to improve light efficiency and extend service life, its use in display and illumination apparatus)

RN 943988-43-0 CAPLUS

CN Iridium, tris[(9,9-dimethyl-9H-fluorene-3,2-diyl)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (CA INDEX NAME)




L4 ANSWER 28 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN


10568344b.trn

ACCESSION NUMBER: 2006:1337747 CAPLUS
 DOCUMENT NUMBER: 146:62927
 TITLE: Process for acid-catalyzed coordinative isomerization
 of electroluminescent platinum-group metal
 cyclometalated N-heterocyclic carbene complexes
 INVENTOR(S): Molt, Oliver; Kahle, Klaus
 PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 40pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006134113	A1	20061221	WO 2006-EP63165	20060613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM DE 102005027548 A1 20061221 DE 2005-102005027548 20050614 EP 1899359 A1 20080319 EP 2006-763686 20060613 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR US 20080200686 A1 20080821 US 2007-916455 20071204 DE 2005-102005027548A 20050614 PRIORITY APPLN. INFO.: WO 2006-EP63165 W 20060613 OTHER SOURCE(S): CASREACT 146:62927; MARPAT 146:62927 GI				



- AB A process for coordinative isomerization, preferably mer-fac-isomerization of cyclometalated carbene complexes I [M = Pd, Pt, Ru, Os, Co, Rh, Ir, preferably M = Ir(III), x = 2, 3; Q3 = NR, O, S, PR1; Q1-Q2C:C = optionally substituted or annelated 1,2-phenylene, furandiyl, thiophenediyl, pyrrolediyl, pyrazole-diyl, isothiazole-diyl, isoxazole-diyl, thiazole-diyl, oxazole-diyl, imidazole-diyl, pyridinediyl, pyridazinediyl; pyrimidinediyl, pyrazinediyl; Y1 = Y2 = H, alkyl, alkenyl, (hetero)aryl, alkoxy, aryloxy, alkylthio, arylthio, acyl, carboxy, ester, sulfono, sulfonate, halo, CN, CHO, NO2, NO; Y1-Y2 = optionally annelated or substituted benzo], useful as luminescent materials for organic light-emitting devices (no data), comprises reaction of the compds. I with 10-5-10-1 M Bronsted acid in a solvent, preferably water, C1-4 alc., ketone, esters, halogenated hydrocarbons, DMF, DMSO. In an example, 27 μ mol of the complex mer-I (Q1-Q2 = CH:C(CN):CHCH, Q3 = NMe, Y1 = Y2 = H; M = Ir, x = 3) was isomerized to a mixture, containing 75% of fac-I and 25% of the starting mer-I by refluxing in 9.75 mL of acetone with addition of 0.25 mL of 0.1 M aqueous HCl for 4 h.
- IT 916910-74-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for Bronsted acid-catalyzed coordinative mer-fac-isomerization of iridium cyclometalated carbene imidazolyli-dene electroluminescent complexes)
- RN 916910-74-2 CAPLUS
- CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, (OC-6-21)- (CA INDEX NAME)



- IT 913636-78-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (process for Bronsted acid-catalyzed coordinative mer-fac-isomerization of iridium cyclometalated carbene imidazolyli-dene electroluminescent complexes)
- RN 913636-78-9 CAPLUS
- CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, (OC-6-22)- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:1147668 CAPLUS
 DOCUMENT NUMBER: 145:480101
 TITLE: Organic electroluminescent device
 INVENTOR(S): Murakami, Takeshi; Yagi, Kazunari; Ichijima, Seiji;
 Igarashi, Tatsuya; Satou, Tasuku
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 122pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006115301	A1	20061102	WO 2006-JP309142	20060425
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
JP 2007096259	A	20070412	JP 2006-119522	20060424
EP 1874894	A1	20080109	EP 2006-745992	20060425
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20090079329	A1	20090326	US 2007-911665	20071016
PRIORITY APPLN. INFO.:			JP 2005-126262	A 20050425

JP 2005-247418 A 20050829
WO 2006-JP309142 W 20060425


OTHER SOURCE(S): MARPAT 145:480101
GI



- AB An organic electroluminescent device is described comprising a pair of electrodes; and at least one organic layer between the pair of electrodes, where the at least one organic layer contains a specific compound with a general formula I (M = a transition metal atom/ion; R11, R12 = (independently) H, a substituent group, R11, R12 may be independently bonded to M or be cyclic; L11 = (ligand) may be bonded to at least one of R11, and R12; X11 = a counter ion; n11 = (integer)0-5; n12 = (integer)1-6; n13 = (integer) 0-3; C = (carbene carbon) may be bonded to R11 and R12 to coordinate with M) in which a transition metal and a carbene carbon are bonded to each other.
- IT 913611-59-3P 913636-78-9P
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(organic electroluminescent device having transition metal complex layer)
- RN 913611-59-3 CAPLUS
- CN Rhodium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, (OC-6-22)- (CA INDEX NAME)



- RN 913636-78-9 CAPLUS
- CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, (OC-6-22)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:714501 CAPLUS

DOCUMENT NUMBER: 145:428680

TITLE: Efficient deep blue triplet emitters for OLEDs

AUTHOR(S): Erk, Peter; Bold, Markus; Egen, Martina; Fuchs, Evelyn; Gessner, Thomas; Kahle, Klaus; Lennartz, Christian; Molt, Oliver; Nord, Simon; Reichelt, Helmut; Schildknecht, Christian; Johannes, Hans-Herrmann; Kowalsky, Wolfgang
CORPORATE SOURCE: BASF Aktiengesellschaft, Ludwigshafen, 67056, Germany
SOURCE: Digest of Technical Papers - Society for Information Display International Symposium (2006), 37(Bk. 1), 131-134

CODEN: DTPSDS

PUBLISHER: Society for Information Display

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Cyclometallated iridium carbene complexes are introduced as efficient blue triplet emitters. Quantum mech. calcns. have been used to design and to optimize this class of materials predominantly with respect to color coordinates and luminescence quantum yield. To complete the set of materials required for deep blue OLED devices we engineered suitable host and blocker materials for the use in combination with large triplet energy carbene emitters. These tailor-made materials were applied to develop deep blue electroluminescent devices with excellent efficiency.

IT 888725-36-8

RL: DEV (Device component use); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(efficient deep blue triplet emitter for organic light-emitting diode)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:632152 CAPLUS

DOCUMENT NUMBER: 145:112952

TITLE: Metal complexes with nucleophilic carbene ligands and devices and processes using them

INVENTOR(S): Pretot, Roger; Van Der Schaaf, Paul Adriaan; Schmidt, Jemima; Schmidhalter, Beat; Schaefer, Thomas; Lamatsch, Bernd

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067074	A1	20060629	WO 2005-EP56767	20051214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2589711	A1	20060629	CA 2005-2589711	20051214
EP 1841834	A1	20071010	EP 2005-817212	20051214
EP 1841834	B1	20090506		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

	IS, I, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR	
CN 101087863	A 20071212	CN 2005-80044163
JP 2008525366	T 20080717	JP 2007-547457
AT 430789	T 20090515	AT 2005-817212
IN 2007CN02780	A 20070907	IN 2007-CN2780
KR 2007091355	A 20070910	KR 2007-716762
PRIORITY APPLN. INFO.:		EP 2004-106916
		WO 2005-EP56767
OTHER SOURCE(S):	MARPAT 145:112952	A 20041223
GI		W 20051214



AB The title compounds are described by the general formula I (ring A = an optionally substituted aryl group which can optionally contain heteroatoms; ring B = an optionally substituted nitrogen-containing aryl group, which can optionally contain further heteroatoms; ring A and ring B may be bonded to form a ring; group C = an acyclic carbene or a cyclic carbene which can optionally contain heteroatoms; ring D = an optionally substituted aryl group which can optionally contain heteroatoms; n1 = 1 = 3, m1 = 0, 1, or 2; m2 = 0 or 1; M1 = a metal with an atomic weight > 40; L3 =

monodentate or bidentate ligand; $Y = -C(=O)-$ or $-C(X_1)_2-$; $X_1 = H$ or Cl -4 alkyl; and $y = 0$ or 1) with the exception of certain specified compds. The use of the compds. is described in electronic devices, especially organic light-emitting diodes, as oxygen-sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts. Organic electronic devices, especially organic light-emitting diodes, comprising an emitting layer which comprises the compds., as well as displays employing the light-emitting diodes, are also described.

IT	847049-63-2	895527-79-4	895527-80-7
	895527-81-8	895527-82-9	895527-83-0
	895527-84-1	895527-85-2	895527-86-3
	895527-87-4	895527-88-5	895527-89-6
	895527-90-9	895527-91-0	895527-92-1
	895527-93-2	895527-94-3	895527-95-4
	895527-96-5	895527-97-6	895527-98-7
	895528-00-4	895528-01-5	895528-02-6
	895528-03-7	895528-04-8	895528-05-9
	895528-06-0	895528-07-1	895528-08-2
	895528-09-3	895528-10-6	895528-11-7
	895528-12-8	895528-13-9	895528-14-0
	895528-15-1	895528-16-2	895528-17-3

895528-18-4 895528-19-5 895528-20-8
895528-21-9 895528-22-0 895528-23-1
895528-24-2 895528-25-3 895528-26-4
895528-27-5 895528-28-6 895528-29-7
895528-31-1 895528-32-2 895528-33-3
895528-35-5 895528-36-6 895528-37-7
895528-38-8 895528-39-9 895528-40-2
895528-41-3 895528-42-4 895528-43-5
895528-44-6 895528-45-7 895528-46-8
895528-47-9 895528-48-0 895528-49-1
895528-50-4 895528-51-5 895528-52-6
895528-53-7 895528-54-8 895528-56-0
895528-58-2 895528-60-6 895528-62-8
895530-49-1 895530-50-4 895530-51-5
895530-52-6 895530-53-7 895530-54-8
895530-55-9 895530-56-0 895530-57-1
895530-58-2 895530-59-3 895530-60-6
895530-61-7 895530-62-8 895530-63-9
895530-64-0 895530-65-1 895530-66-2
895530-67-3 895530-68-4 895530-69-5
895530-70-8 895530-71-9 895530-72-0
895530-73-1 895530-74-2 895530-75-3
895530-76-4 895530-77-5 895530-78-6
895530-79-7 895530-80-0 895530-81-1
895530-82-2 895530-83-3 895530-84-4
895530-85-5 895530-86-6 895530-87-7
895530-88-8 895530-89-9 895530-90-2
895530-91-3 895530-92-4 895530-93-5
895530-94-6 895530-95-7 895530-96-8
895530-97-9 895530-98-0 895530-99-1
895531-00-7 895531-01-8 895531-02-9
895531-03-0 895531-04-1 895531-05-2
895531-06-3 895531-07-4 895531-08-5
895551-13-0 895551-14-1 895551-15-2
895551-16-3 895551-17-4 895551-18-5
895551-19-6 895551-20-9 895551-21-0
895551-22-1 895551-23-2 895551-24-3
895551-25-4 895551-26-5 895551-27-6
895551-28-7 895551-29-8 895551-30-1
895551-31-2 895551-32-3 895551-33-4
895551-34-5 895551-35-6 895551-36-7
895551-37-8 895551-38-9 895551-39-0
895551-40-3 895551-41-4 895551-42-5
895551-43-6 895551-44-7 895551-45-8
895551-46-9 895551-47-0 895551-48-1
895551-49-2 895551-50-5 895551-51-6
895551-52-7 895551-53-8 895551-54-9
895551-55-0 895551-56-1 895551-57-2
895551-58-3 895551-59-4 895551-60-7
895551-61-8 895551-62-9 895551-63-0
895551-64-1 895551-65-2 895551-66-3
895551-67-4 895551-68-5 895551-69-6
895551-70-9 895551-71-0 895551-72-1
895551-73-2 895551-74-3 895551-75-4
895551-76-5 895551-77-6 895551-78-7
895551-79-8 895551-80-1 895551-81-2
895551-82-3 895551-83-4 895551-84-5


895551-85-6 895551-86-7 895551-87-8
 895551-88-9 895551-89-0 895551-90-3
 895551-91-4 895551-92-5 895551-93-6
 895551-94-7 895551-95-8 895551-97-0
 895551-98-1 895552-00-8 895552-02-0
 895552-04-2 895552-05-3 895552-07-5
 895552-09-7 895552-11-1 895552-13-3
 895552-15-5 895552-17-7 895552-18-8
 895552-19-9 895552-20-2 895552-21-3
 895552-22-4

RL: DEV (Device component use); USES (Uses)

(metal complexes with nucleophilic carbene ligands and devices and processes using them)


RN 847049-63-2 CAPLUS

CN Iridium, tris[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI)
 (CA INDEX NAME)



RN 895527-79-4 CAPLUS


CN Platinum, [5-(3-methoxy-3-oxopropyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895527-80-7 CAPLUS


CN Platinum, [2',3',4',5',6'-pentafluoro-4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-

ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-81-8 CAPLUS

CN Platinum, [2-methyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-82-9 CAPLUS


CN Platinum, [4-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895527-83-0 CAPLUS
 CN Platinum, [2-ethenyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-84-1 CAPLUS
 CN Platinum, [4-ethenyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-85-2 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][3-(2-pyridinyl-κN)[1,1'-biphenyl]-2-yl-κC]- (9CI) (CA INDEX NAME)



RN 895527-86-3 CAPLUS


CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC]- (9CI) (CA INDEX NAME)



RN 895527-87-4 CAPLUS


CN Platinum, [2',3',4',5',6'-pentafluoro-3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)






RN 895527-88-5 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-4,6-bis(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895527-89-6 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895527-90-9 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895527-91-0 CAPLUS

CN Platinum, [4-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-92-1 CAPLUS

CN Platinum, [2-fluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-93-2 CAPLUS

CN Platinum, [2,4-difluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-94-3 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-6-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895527-95-4 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-4-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895527-96-5 CAPLUS

CN Platinum, [4-nitro-2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895527-97-6 CAPLUS
 CN Platinum, [2-nitro-6-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895527-98-7 CAPLUS

CN Platinum, [4-cyano-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-00-4 CAPLUS

CN Platinum, [2-cyano-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-01-5 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-6-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-02-6 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-4-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-03-7 CAPLUS

CN Platinum, [2-cyano-4-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895528-04-8 CAPLUS


CN Platinum, [4-cyano-2-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-05-9 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-[6-

(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895528-06-0 CAPLUS
CN Platinum, [2-(6-chloro-2-pyridinyl-κN)phenyl-κC] [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895528-07-1 CAPLUS
 CN Platinum, [2-(6-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895528-08-2 CAPLUS
 CN Platinum, [2-(6-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895528-09-3 CAPLUS
CN Platinum, [2-(6-methyl-2-pyridinyl-κN)phenyl-κC] [1,2-

phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895528-10-6 CAPLUS

CN Platinum, [2-(6-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895528-11-7 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(6-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895528-12-8 CAPLUS
 CN Platinum, [2-(6-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 895528-13-9 CAPLUS


CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-[3-

(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-14-0 CAPLUS

CN Platinum, [2-(3-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-15-1 CAPLUS


CN Platinum, [2-(3-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-16-2 CAPLUS
 CN Platinum, [2-(3-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-17-3 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(3-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-18-4 CAPLUS
 CN Platinum, [2-(3-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-19-5 CAPLUS
 CN Platinum, [2-(3-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-20-8 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(4-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-21-9 CAPLUS
 CN Platinum, [2-(4-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895528-22-0 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(5-(trifluoromethyl)-2-pyridinyl-kN)phenyl-kC]- (9CI) (CA INDEX NAME)




RN 895528-23-1 CAPLUS
 CN Platinum, [2-(5-methyl-2-pyridinyl-kN)phenyl-kC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-24-2 CAPLUS

CN Platinum, [2-(5-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-25-3 CAPLUS

CN Platinum, [2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-26-4 CAPLUS

CN Platinum, [2-[4-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-27-5 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(5-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-28-6 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(4-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-29-7 CAPLUS

CN Platinum, [3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-31-1 CAPLUS

CN Platinum, [5-fluoro-2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-32-2 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-33-3 CAPLUS

CN Platinum, [4-[dimethyl(tridecafluorohexyl)silyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-35-5 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][5-fluoro-2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-36-6 CAPLUS

CN Platinum, [2-[5-(pentafluorophenyl)-2-pyridinyl-κN]-5-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-37-7 CAPLUS


CN Platinum, [2',3',4',5',6'-pentafluoro-3-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895528-38-8 CAPLUS
 CN Platinum, [2',3',4',5',6'-pentafluoro-4-[5-(pentafluorophenyl)-2-pyridinyl- κ N][1,1'-biphenyl]-3-yl- κ C][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-39-9 CAPLUS
 CN Platinum, [2',3',4',5',6'-pentafluoro-3-[4-(pentafluorophenyl)-2-pyridinyl- κ N][1,1'-biphenyl]-4-yl- κ C][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-40-2 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-4-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-41-3 CAPLUS

CN Platinum, [4-cyano-3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-42-4 CAPLUS

CN Platinum, [2-(4-methoxy-2-pyridinyl-κN)-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-43-5 CAPLUS

CN Platinum, [2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-44-6 CAPLUS

CN Platinum, [4-cyano-2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-45-7 CAPLUS

CN Platinum, [2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-46-8 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-quinolinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895528-47-9 CAPLUS

CN Platinum, [5-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-48-0 CAPLUS

CN Platinum, [5-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-49-1 CAPLUS


CN Platinum, [5-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-50-4 CAPLUS
 CN Platinum, [4-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-51-5 CAPLUS
 CN Platinum, [4-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895528-52-6 CAPLUS
 CN Platinum, [4-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-53-7 CAPLUS
 CN Platinum, [2-(1-isoquinolinyl-κN)-5-methylphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-54-8 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)-5-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-56-0 CAPLUS

CN Platinum, [5-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-58-2 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)-4-methylphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-60-6 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)-4-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895528-62-8 CAPLUS

CN Platinum, [4-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-49-1 CAPLUS

CN Platinum, bis[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-50-4 CAPLUS

CN Platinum, bis[(5-nitro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-51-5 CAPLUS

CN Platinum, bis[(5-methyl-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-52-6 CAPLUS

CN Platinum, bis[[5-(1,1-dimethylethyl)-1,2-phenylene] (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-53-7 CAPLUS

CN Platinum, bis[[5-(1-methylethyl)-1,2-phenylene] (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-54-8 CAPLUS

CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[4-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-55-9 CAPLUS

CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[4-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-56-0 CAPLUS

CN Platinum, bis[(5-fluoro-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-57-1 CAPLUS

CN Platinum, bis[(5-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-58-2 CAPLUS

CN Platinum, bis[(5-phenoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-59-3 CAPLUS

CN Platinum, bis[(5-cyano-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-60-6 CAPLUS

CN Platinum, bis[[5-(methylthio)-1,2-phenylene] (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-61-7 CAPLUS

CN Platinum, bis[[5-(methoxycarbonyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-62-8 CAPLUS

CN Platinum, bis[[5-(methylsulfonyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-63-9 CAPLUS

CN Platinum, bis[(6-methyl-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-64-0 CAPLUS

CN Platinum, bis[(6-fluoro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-65-1 CAPLUS


CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene) [3-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)



RN 895530-66-2 CAPLUS
 CN Platinum, bis[(6-(1,1-dimethylethyl)-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-67-3 CAPLUS
 CN Platinum, bis[(6-cyano-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-68-4 CAPLUS

CN Platinum, bis[(6-nitro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-69-5 CAPLUS


CN Platinum, bis[(6-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-70-8 CAPLUS
 CN Platinum, bis[(4-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895530-71-9 CAPLUS
 CN Platinum, bis[(4-fluoro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-72-0 CAPLUS
 CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene) [5-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-73-1 CAPLUS

CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]-5-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-74-2 CAPLUS

CN Platinum, bis[(4-cyano-1,2-phenylene)]-(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-75-3 CAPLUS

CN Platinum, bis[(4-nitro-1,2-phenylene)]-(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-76-4 CAPLUS

CN Platinum, bis[(4-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-77-5 CAPLUS

CN Platinum, bis[[4-(methylthio)-1,2-phenylene] (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-78-6 CAPLUS

CN Platinum, bis[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene) [4'-(trifluoromethyl) [1,1'-biphenyl]-4,3-diyl]]- (9CI) (CA INDEX NAME)




RN 895530-79-7 CAPLUS


CN Platinum, bis[1,2-phenylene (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-80-0 CAPLUS
 CN Platinum, bis[(5-nitro-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895530-81-1 CAPLUS
 CN Platinum, bis[(5-methyl-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-82-2 CAPLUS
 CN Platinum, bis[(5-(1,1-dimethylethyl)-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-83-3 CAPLUS

CN Platinum, bis[[5-(1-methylethyl)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-84-4 CAPLUS

CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene)[4-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-85-5 CAPLUS

CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene)[4-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895530-86-6 CAPLUS


CN Platinum, bis[(5-fluoro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-87-7 CAPLUS
 CN Platinum, bis[(5-methoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895530-88-8 CAPLUS
 CN Platinum, bis[(5-phenoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-89-9 CAPLUS
 CN Platinum, bis[(5-cyano-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-90-2 CAPLUS

CN Platinum, bis[[5-(methylthio)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-91-3 CAPLUS

CN Platinum, bis[[5-(methoxycarbonyl)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-92-4 CAPLUS

CN Platinum, bis[[5-(methylsulfonyl)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-93-5 CAPLUS

CN Platinum, bis[[6-methyl-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-94-6 CAPLUS

CN Platinum, bis[(6-fluoro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-95-7 CAPLUS


CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene) [3-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)



RN 895530-96-8 CAPLUS
 CN Platinum, bis[(6-(1,1-dimethylethyl)-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-97-9 CAPLUS
 CN Platinum, bis[(6-cyano-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-98-0 CAPLUS

CN Platinum, bis[(6-nitro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895530-99-1 CAPLUS


CN Platinum, bis[(6-methoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-00-7 CAPLUS
 CN Platinum, bis[(4-methyl-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895531-01-8 CAPLUS
 CN Platinum, bis[(4-fluoro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-02-9 CAPLUS
 CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene) [5-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895531-03-0 CAPLUS

CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene)[5-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895531-04-1 CAPLUS

CN Platinum, bis[(4-cyano-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-05-2 CAPLUS

CN Platinum, bis[(4-nitro-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-06-3 CAPLUS

CN Platinum, bis[(4-methoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-07-4 CAPLUS

CN Platinum, bis[[4-(methylthio)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895531-08-5 CAPLUS

CN Platinum, bis[(3-phenyl-1-imidazolidinyl-2-ylidene) [4'-(trifluoromethyl) [1,1'-biphenyl]-4,3-diyl]]- (9CI) (CA INDEX NAME)




RN 895551-13-0 CAPLUS


CN Iridium, [1,2-phenylene (3-phenyl-1H-imidazol-1-yl-2 (3H)-ylidene)] bis[2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-14-1 CAPLUS
 CN Iridium, bis[5-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-15-2 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC]- (9CI) (CA INDEX NAME)




RN 895551-16-3 CAPLUS
 CN Iridium, bis[5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895551-17-4 CAPLUS
 CN Iridium, bis[5-cyclohexyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-18-5 CAPLUS
 CN Iridium, bis[5-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-19-6 CAPLUS
 CN Iridium, bis[5-methoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-20-9 CAPLUS
 CN Iridium, bis[5-phenoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-21-0 CAPLUS
 CN Iridium, bis[5-(phenyloxy)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-22-1 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-5-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-23-2 CAPLUS
 CN Iridium, bis[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-24-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-5-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-25-4 CAPLUS


CN Iridium, bis[5-(methylthio)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-26-5 CAPLUS
 CN Iridium, bis[5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895551-27-6 CAPLUS
 CN Iridium, bis[5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895551-28-7 CAPLUS

CN Iridium, bis[5-mercapto-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-29-8 CAPLUS

CN Iridium, bis[5-nitro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-30-1 CAPLUS

CN Iridium, bis[5-(dimethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-31-2 CAPLUS

CN Iridium, bis[5-amino-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-32-3 CAPLUS

CN Iridium, bis[5-(acetylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-33-4 CAPLUS

CN Iridium, bis[5-[(methylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-34-5 CAPLUS

CN Iridium, bis[5-(ethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-35-6 CAPLUS


CN Iridium, bis[5-formyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-36-7 CAPLUS
 CN Iridium, bis[5-(hydroxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895551-37-8 CAPLUS
 CN Iridium, bis[5-(bromomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-38-9 CAPLUS

CN Iridium, bis[5-(cyanomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-39-0 CAPLUS

CN Iridate(2-), bis[5-(carboxylatomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]-, dihydrogen (9CI) (CA INDEX NAME)




RN 895551-40-3 CAPLUS

CN Iridium, bis[5-(methoxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-41-4 CAPLUS

CN Iridium, bis[5-[(diethylamino)methyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-42-5 CAPLUS

CN Iridium, bis[5-(3-methoxy-3-oxo-1-propenyl)-2-(2-pyridinyl-κN)phenyl-κC[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-43-6 CAPLUS

CN Iridium, bis[5-(3-methoxy-3-oxopropyl)-2-(2-pyridinyl-κN)phenyl-κC[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-44-7 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 895551-45-8 CAPLUS
 CN Iridium, bis[2-methyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-46-9 CAPLUS
 CN Iridium, bis[4-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-47-0 CAPLUS
 CN Iridium, bis[2-ethenyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-


phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-48-1 CAPLUS
CN Iridium, bis[4-ethenyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-49-2 CAPLUS
CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[3-(2-pyridinyl-κN)[1,1'-biphenyl]-2-yl-κC]- (9CI) (CA INDEX NAME)




RN 895551-50-5 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC]- (9CI) (CA INDEX NAME)




RN 895551-51-6 CAPLUS


CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-52-7 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-4,6-bis(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-53-8 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-54-9 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-55-0 CAPLUS
 CN Iridium, bis[4-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-56-1 CAPLUS
 CN Iridium, bis[2-fluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-57-2 CAPLUS
 CN Iridium, bis[2,4-difluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-58-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-59-4 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-60-7 CAPLUS

CN Iridium, bis[4-nitro-2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-61-8 CAPLUS


CN Iridium, bis[2-nitro-6-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)



RN 895551-62-9 CAPLUS
 CN Iridium, bis[4-cyano-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-63-0 CAPLUS
 CN Iridium, bis[2-cyano-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-64-1 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-65-2 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-66-3 CAPLUS

CN Iridium, bis[2-cyano-4-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-67-4 CAPLUS


CN Iridium, bis[4-cyano-2-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-68-5 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(6-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-69-6 CAPLUS
 CN Iridium, bis[2-(6-chloro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-70-9 CAPLUS

CN Iridium, bis[2-(6-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-71-0 CAPLUS

CN Iridium, bis[2-(6-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-72-1 CAPLUS

CN Iridium, bis[2-(6-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-73-2 CAPLUS

CN Iridium, bis[2-(6-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-74-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(6-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-75-4 CAPLUS

CN Iridium, bis[2-(6-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-76-5 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(3-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-77-6 CAPLUS


CN Iridium, bis[2-(3-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-78-7 CAPLUS
 CN Iridium, bis[2-(3-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-79-8 CAPLUS
 CN Iridium, bis[2-(3-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-80-1 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(3-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-81-2 CAPLUS

CN Iridium, bis[2-(3-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-82-3 CAPLUS

CN Iridium, bis[2-(3-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-83-4 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(4-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-84-5 CAPLUS

CN Iridium, bis[2-(4-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-85-6 CAPLUS


CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895551-86-7 CAPLUS
 CN Iridium, bis[2-(5-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)





RN 895551-87-8 CAPLUS
 CN Iridium, bis[2-(5-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895551-88-9 CAPLUS
 CN Iridium, bis[2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)


PAGE 1-A






RN 895551-89-0 CAPLUS

CN Iridium, bis[2-[4-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895551-90-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(5-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-91-4 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(4-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895551-92-5 CAPLUS

CN Iridium, bis[3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-93-6 CAPLUS

CN Iridium, bis[5-fluoro-2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-94-7 CAPLUS

CN Iridium, bis[2-(1-isoquinolinylyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-95-8 CAPLUS

CN Iridium, bis[4-[dimethyl(tridecafluorohexyl)silyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895551-97-0 CAPLUS
 CN Iridium, bis[5-fluoro-2-(5-(pentafluorophenyl)-2-pyridinyl)-κN]phenyl-
 κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl)-2-(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895551-98-1 CAPLUS
 CN Iridium, bis[2-[5-(pentafluorophenyl)-2-pyridinyl-κN]-5-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl)-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895552-00-8 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-

1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895552-02-0 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 895552-04-2 CAPLUS

CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 895552-05-3 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-[4-(pentafluorophenyl)-2-pyridinyl-κN] [1,1'-biphenyl]-3-yl-κC] [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895552-07-5 CAPLUS

CN Iridium, bis[4-cyano-3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895552-09-7 CAPLUS

CN Iridium, bis[2-(4-methoxy-2-pyridinyl-κN)-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-11-1 CAPLUS


CN Iridium, bis[2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895552-13-3 CAPLUS
 CN Iridium, bis[4-cyano-2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-15-5 CAPLUS
 CN Iridium, bis[2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-17-7 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[2-(2-quinolinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-18-8 CAPLUS

CN Iridium, bis[5-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895552-19-9 CAPLUS


CN Iridium, bis[5-methoxy-2-(2-quinoliny1-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895552-20-2 CAPLUS


CN Iridium, bis[5-(dimethylamino)-2-(2-quinoliny1-κN)phenyl-

$\kappa\text{C}[1,2\text{-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]^-$ (9CI)
(CA INDEX NAME)




RN 895552-21-3 CAPLUS

CN Iridium, bis[4-methyl-2-(2-quinolinyl- κN)phenyl- κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895552-22-4 CAPLUS

CN Iridium, bis[4-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




IT 895552-23-5 895552-24-6 895552-25-7
 895552-26-8 895552-27-9 895552-28-0
 895552-29-1 895552-30-4 895552-31-5
 895552-32-6 895552-33-7 895552-34-8
 895552-35-9 895552-36-0 895552-37-1
 895552-38-2 895552-39-3 895552-40-6
 895552-41-7 895552-42-8 895552-43-9
 895552-44-0 895552-45-1 895552-46-2
 895552-47-3 895552-48-4 895552-49-5
 895552-50-8 895552-51-9 895552-52-0
 895552-53-1 895552-54-2 895552-55-3
 895552-56-4 895552-57-5 895552-58-6
 895552-59-7 895552-60-0 895552-61-1
 895552-62-2 895552-63-3 895552-64-4
 895552-65-5 895552-66-6 895552-67-7
 895552-68-8 895552-69-9 895552-70-2
 895552-71-3 895552-72-4 895552-73-5
 895552-74-6 895552-75-7 895552-76-8
 895552-77-9 895552-78-0 895552-79-1
 895552-80-4 895552-81-5 895552-82-6
 895552-83-7 895552-84-8 895552-85-9
 895552-86-0 895552-87-1 895552-88-2
 895552-89-3 895552-90-6 895552-91-7
 895552-92-8 895552-93-9 895552-94-0
 895552-95-1 895552-96-2 895552-97-3
 895552-98-4 895552-99-5 895553-00-1

895553-01-2 895553-02-3 895553-03-4
 895553-04-5 895553-05-6 895553-06-7
 895553-07-8 895553-08-9 895553-09-0
 895553-10-3 895553-11-4 895553-12-5
 895553-13-6 895553-14-7 895553-15-8
 895553-16-9 895553-17-0 895553-18-1
 895553-19-2 895553-20-5 895553-21-6
 895553-22-7 895553-23-8 895553-24-9
 895553-25-0 895553-26-1 895553-27-2
 895553-28-3 895553-29-4 895553-30-7
 895553-31-8 895553-32-9 895553-33-0
 895553-34-1 895553-35-2 895553-36-3
 895553-37-4 895553-38-5 895553-39-6
 895553-40-9 895553-41-0 895553-42-1
 895553-43-2 895553-44-3 895553-45-4
 895553-46-5 895553-47-6 895553-48-7
 895553-49-8 895553-50-1 895553-51-2
 895553-52-3 895553-53-4 895553-54-5
 895553-55-6 895553-56-7 895553-57-8
 895553-58-9 895553-59-0 895553-60-3
 895553-61-4 895553-62-5 895553-63-6
 895553-64-7 895553-65-8 895553-66-9
 895553-67-0 895553-68-1 895553-69-2
 895553-70-5 895553-71-6 895553-72-7
 895553-73-8 895553-74-9 895553-75-0
 895553-76-1 895553-77-2 895553-78-3
 895553-79-4 895553-80-7 895553-81-8
 895553-82-9 895553-83-0 895553-84-1
 895553-85-2 895553-86-3 895553-87-4
 895553-88-5 895553-89-6 895553-90-9
 895553-91-0 895553-93-2 895553-94-3
 895553-95-4 895553-96-5 895553-97-6
 895553-98-7 895553-99-8 895554-00-4
 895554-01-5 895554-02-6 895554-03-7
 895554-04-8 895554-05-9 895554-06-0
 895554-07-1 895554-08-2 895554-09-3
 895554-10-6 895554-11-7 895554-12-8
 895554-13-9 895554-14-0 895554-15-1
 895554-16-2 895556-02-2 895556-03-3
 895556-04-4 895556-05-5 895556-06-6
 895556-07-7 895556-08-8 895556-09-9
 895556-10-2 895556-11-3 895556-12-4
 895556-13-5 895556-14-6 895556-15-7
 895556-16-8 895556-17-9 895556-18-0
 895556-19-1 895556-20-4 895556-21-5
 895556-22-6 895556-23-7 895556-24-8
 895556-25-9 895556-26-0 895556-27-1
 895556-28-2 895556-29-3 895556-30-6
 895556-31-7 895556-32-8 895556-33-9
 895556-34-0 895556-35-1 895556-36-2
 895556-37-3 895556-38-4 895556-39-5
 895556-40-8 895556-41-9 895556-42-0
 895556-43-1 895556-44-2 895556-45-3
 895556-46-4

RL: DEV (Device component use); USES (Uses)
 (metal complexes with nucleophilic carbene ligands and devices and
 processes using them)


RN 895552-23-5 CAPLUS

CN Iridium, bis[4-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)



RN 895552-24-6 CAPLUS


CN Iridium, bis[2-(1-isoquinolinyl-κN)-5-methylphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895552-25-7 CAPLUS


CN Iridium, bis[2-(1-isoquinolinyl-κN)-5-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

NAME)




RN 895552-26-8 CAPLUS

CN Iridium, bis[5-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895552-27-9 CAPLUS

CN Iridium, bis[2-(1-isoquinolinyl-κN)-4-methylphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-28-0 CAPLUS

CN Iridium, bis[2-(1-isoquinolinyl-κN)-4-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-29-1 CAPLUS

CN Iridium, bis[4-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895552-30-4 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-31-5 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-methyl-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-32-6 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC]-(9CI) (CA INDEX NAME)




RN 895552-33-7 CAPLUS
 CN Iridium, bis[5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)




RN 895552-34-8 CAPLUS
 CN Iridium, bis[5-cyclohexyl-2-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-35-9 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-fluoro-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-36-0 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-methoxy-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-37-1 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-phenoxy-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-38-2 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-hydroxy-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-39-3 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-5-(trifluoromethoxy)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-40-6 CAPLUS
 CN Iridium, bis[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(2-pyridinyl- κ N)phenyl- κ C] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-41-7 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl- κ N)-5-(trifluoromethyl)phenyl- κ C]- (9CI) (CA INDEX NAME)



RN 895552-42-8 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(methylthio)-2-(2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-43-9 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-44-0 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(methylsulfinyl)-2-(2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-45-1 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-mercapto-2-(2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)



RN 895552-46-2 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(2-mercaptophenyl)-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-47-3 CAPLUS
 CN Iridium, bis[5-(dimethylamino)-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-48-4 CAPLUS

CN Iridium, bis[5-amino-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-49-5 CAPLUS


CN Iridium, bis[5-(acetylamino)-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-50-8 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(methylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-51-9 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(ethylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-52-0 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-formyl-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-53-1 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(hydroxymethyl)-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-54-2 CAPLUS
 CN Iridium, bis[5-(bromomethyl)-2-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)



RN 895552-55-3 CAPLUS
 CN Iridium, bis[5-(cyanomethyl)-2-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-56-4 CAPLUS
 CN Iridate(2-), bis[5-(carboxylatomethyl)-2-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-, dihydrogen (9CI) (CA INDEX NAME)




● 2 H⁺

RN 895552-57-5 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(methoxymethyl)-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-58-6 CAPLUS

CN Iridium, bis[5-[(diethylamino)methyl]-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)




RN 895552-59-7 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(3-methoxy-3-oxo-1-propenyl)-2-(2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)



RN 895552-60-0 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[5-(3-methoxy-3-oxopropyl)-2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895552-61-1 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2',3',4',5',6'-pentafluoro-4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895552-62-2 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-methyl-6-(2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-63-3 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[4-methyl-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-64-4 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-ethenyl-6-(2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)



RN 895552-65-5 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[4-ethenyl-2-(2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-66-6 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[3-(2-pyridinyl-κN)[1,1'-biphenyl]-2-yl-κC]- (9CI)
 (CA INDEX NAME)




RN 895552-67-7 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[3-(2-pyridinyl-κN) [1,1'-biphenyl]-4-yl-κC]-(9CI) (CA INDEX NAME)




RN 895552-68-8 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2',3',4',5',6'-pentafluoro-3-(2-pyridinyl-κN) [1,1'-biphenyl]-4-yl-κC]-(9CI) (CA INDEX NAME)




RN 895552-69-9 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-4,6-bis(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 895552-70-2 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-71-3 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-72-4 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[4-fluoro-2-(2-pyridinyl-κN)phenyl-κC]-(9CI)

(CA INDEX NAME)




RN 895552-73-5 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-fluoro-6-(2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-74-6 CAPLUS

CN Iridium, bis[2,4-difluoro-6-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-75-7 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-6-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-76-8 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-4-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-77-9 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[4-nitro-2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 895552-78-0 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-nitro-6-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-79-1 CAPLUS
 CN Iridium, bis[4-cyano-2-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-80-4 CAPLUS
 CN Iridium, bis[2-cyano-6-(2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)

NAME)




RN 895552-81-5 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-6-(trimethylsilyl)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-82-6 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(2-pyridinyl-κN)-4-(trimethylsilyl)phenyl-κC]-(9CI) (CA INDEX NAME)



RN 895552-83-7 CAPLUS
 CN Iridium, bis[2-cyano-4-nitro-6-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-84-8 CAPLUS
 CN Iridium, bis[4-cyano-2-nitro-6-(2-pyridinyl-κN)phenyl-κC] [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-85-9 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-86-0 CAPLUS

CN Iridium, bis[2-(6-chloro-2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)




RN 895552-87-1 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-nitro-2-pyridinyl-kappaN)phenyl-kappaC]- (9CI) (CA INDEX NAME)




RN 895552-88-2 CAPLUS

CN Iridium, bis[2-(6-cyano-2-pyridinyl-kappaN)phenyl-kappaC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]- (9CI) (CA INDEX NAME)




RN 895552-89-3 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-methyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-90-6 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-methoxy-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-91-7 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-92-8 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(6-fluoro-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-93-9 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[3-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]-(9CI) (CA INDEX NAME)




RN 895552-94-0 CAPLUS

CN Iridium, bis[2-(3-cyano-2-pyridinyl-κN)phenyl-κC][(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)




RN 895552-95-1 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(3-nitro-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-96-2 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(3-methyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895552-97-3 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(3-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-98-4 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(3-fluoro-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895552-99-5 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(3-methoxy-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-00-1 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[4-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-01-2 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(4-methyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895553-02-3 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI)
(CA INDEX NAME)



RN 895553-03-4 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(5-methyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895553-04-5 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(5-fluoro-2-pyridinyl-κN)phenyl-κC]- (9CI)
 (CA INDEX NAME)




RN 895553-05-6 CAPLUS


CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(5-(pentafluorophenyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 895553-06-7 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-[4-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-07-8 CAPLUS
 CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(5-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-08-9 CAPLUS

CN Iridium, [(3,5-diphenyl-1H-imidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]bis[2-(4-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI)
(CA INDEX NAME)




RN 895553-09-0 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-10-3 CAPLUS

CN Iridium, bis[5-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-11-4 CAPLUS


CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC]- (9CI) (CA INDEX NAME)




RN 895553-12-5 CAPLUS
 CN Iridium, bis[5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-13-6 CAPLUS
 CN Iridium, bis[5-cyclohexyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-14-7 CAPLUS
 CN Iridium, bis[5-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-15-8 CAPLUS
 CN Iridium, bis[5-methoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-16-9 CAPLUS
 CN Iridium, bis[5-phenoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-17-0 CAPLUS
 CN Iridium, bis[5-hydroxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-18-1 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-5-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-19-2 CAPLUS
 CN Iridium, bis[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-20-5 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-5-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-21-6 CAPLUS
 CN Iridium, bis[5-(methylthio)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-22-7 CAPLUS
 CN Iridium, bis[5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-
 κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA
 INDEX NAME)




RN 895553-23-8 CAPLUS
 CN Iridium, bis[5-(methylsulfinyl)-2-(2-pyridinyl-κN)phenyl-
 κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA
 INDEX NAME)




RN 895553-24-9 CAPLUS

CN Iridium, bis[5-mercapto-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-25-0 CAPLUS

CN Iridium, bis[5-nitro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-26-1 CAPLUS

CN Iridium, bis[5-(dimethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-27-2 CAPLUS


CN Iridium, bis[5-amino-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-28-3 CAPLUS
 CN Iridium, bis[5-(acetyl-amino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-29-4 CAPLUS
 CN Iridium, bis[5-[(methylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-30-7 CAPLUS
 CN Iridium, bis[5-(ethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-31-8 CAPLUS
 CN Iridium, bis[5-formyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-32-9 CAPLUS
 CN Iridium, bis[5-(hydroxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-33-0 CAPLUS
 CN Iridium, bis[5-(bromomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-34-1 CAPLUS
 CN Iridium, bis[5-(cyanomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-35-2 CAPLUS
 CN Iridate(2-), bis[5-(carboxylatomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, dihydrogen (9CI) (CA INDEX NAME)




RN 895553-36-3 CAPLUS

CN Iridium, bis[5-(methoxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-37-4 CAPLUS


CN Iridium, bis[5-[(diethylamino)methyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-38-5 CAPLUS
 CN Iridium, bis[5-(3-methoxy-3-oxo-1-propenyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-39-6 CAPLUS
 CN Iridium, bis[5-(3-methoxy-3-oxopropyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-40-9 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 895553-41-0 CAPLUS
 CN Iridium, bis[2-methyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-42-1 CAPLUS
 CN Iridium, bis[4-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-43-2 CAPLUS
 CN Iridium, bis[2-ethenyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-44-3 CAPLUS
 CN Iridium, bis[4-ethenyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-45-4 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[3-(2-pyridinyl-κN)[1,1'-biphenyl]-2-yl-κC]- (9CI) (CA INDEX NAME)




RN 895553-46-5 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC]- (9CI) (CA INDEX NAME)




RN 895553-47-6 CAPLUS


CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-48-7 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-4,6-bis(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-49-8 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895553-50-1 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-51-2 CAPLUS
 CN Iridium, bis[4-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-52-3 CAPLUS

CN Iridium, bis[2-fluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-53-4 CAPLUS


CN Iridium, bis[2,4-difluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-54-5 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-55-6 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-56-7 CAPLUS
 CN Iridium, bis[4-nitro-2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-57-8 CAPLUS
 CN Iridium, bis[2-nitro-6-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-58-9 CAPLUS
 CN Iridium, bis[4-cyano-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-59-0 CAPLUS
 CN Iridium, bis[2-cyano-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-60-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-6-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-61-4 CAPLUS


CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-pyridinyl-κN)-4-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-62-5 CAPLUS
 CN Iridium, bis[2-cyano-4-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-63-6 CAPLUS
 CN Iridium, bis[4-cyano-2-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-64-7 CAPLUS
 CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(6-(trifluoromethyl)-(2-pyridinyl-κN)]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-65-8 CAPLUS
 CN Iridium, bis[2-(6-chloro-2-pyridinyl-κN)]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-66-9 CAPLUS
 CN Iridium, bis[2-(6-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-67-0 CAPLUS
 CN Iridium, bis[2-(6-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-68-1 CAPLUS
 CN Iridium, bis[2-(6-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-69-2 CAPLUS
 CN Iridium, bis[2-(6-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-70-5 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(6-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-71-6 CAPLUS

CN Iridium, bis[2-(6-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-72-7 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(3-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-73-8 CAPLUS


CN Iridium, bis[2-(3-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-74-9 CAPLUS
 CN Iridium, bis[2-(3-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-75-0 CAPLUS
 CN Iridium, bis[2-(3-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-76-1 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(3-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-77-2 CAPLUS

CN Iridium, bis[2-(3-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-78-3 CAPLUS

CN Iridium, bis[2-(3-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-79-4 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-[4-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-80-7 CAPLUS

CN Iridium, bis[2-(4-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-81-8 CAPLUS


CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(5-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895553-82-9 CAPLUS
 CN Iridium, bis[2-(5-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)





RN 895553-83-0 CAPLUS
 CN Iridium, bis[2-(5-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895553-84-1 CAPLUS
 CN Iridium, bis[2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 895553-85-2 CAPLUS

CN Iridium, bis[2-[4-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-86-3 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(5-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-87-4 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(4-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895553-88-5 CAPLUS

CN Iridium, bis[3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-89-6 CAPLUS

CN Iridium, bis[5-fluoro-2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-90-9 CAPLUS

CN Iridium, bis[2-(1-isoquinolinylyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-91-0 CAPLUS

CN Iridium, bis[4-[dimethyl(tridecafluorohexyl)silyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895553-93-2 CAPLUS
 CN Iridium, bis[5-fluoro-2-(5-(pentafluorophenyl)-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895553-94-3 CAPLUS
 CN Iridium, bis[2-[5-(pentafluorophenyl)-2-pyridinyl-κN]-5-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895553-95-4 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1-

imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895553-96-5 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 895553-97-6 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-3-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 895553-98-7 CAPLUS
 CN Iridium, bis[2',3',4',5',6'-pentafluoro-4-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 895553-99-8 CAPLUS
 CN Iridium, bis[4-cyano-3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-00-4 CAPLUS

CN Iridium, bis[2-(4-methoxy-2-pyridinyl-κN)-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-01-5 CAPLUS


CN Iridium, bis[2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895554-02-6 CAPLUS
 CN Iridium, bis[4-cyano-2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-03-7 CAPLUS
 CN Iridium, bis[2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-04-8 CAPLUS

CN Iridium, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis[2-(2-quinolinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895554-05-9 CAPLUS

CN Iridium, bis[5-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895554-06-0 CAPLUS


CN Iridium, bis[5-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895554-07-1 CAPLUS


CN Iridium, bis[5-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA

INDEX NAME)




RN 895554-08-2 CAPLUS

CN Iridium, bis[4-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-09-3 CAPLUS

CN Iridium, bis[4-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-10-6 CAPLUS

CN Iridium, bis[4-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-11-7 CAPLUS

CN Iridium, bis[2-(1-isoquinolinyl-κN)-5-methylphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-12-8 CAPLUS

CN Iridium, bis[2-(1-isoquinolinyl-κN)-5-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-13-9 CAPLUS

CN Iridium, bis[5-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-14-0 CAPLUS

CN Iridium, bis[2-(1-isoquinolinyl-κN)-4-methylphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895554-15-1 CAPLUS


CN Iridium, bis[2-(1-isoquinolinyl-κN)-4-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895554-16-2 CAPLUS
 CN Iridium, bis[4-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidiny-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-02-2 CAPLUS
 CN Iridium, tris[1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-03-3 CAPLUS

CN Iridium, tris[(5-nitro-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895556-04-4 CAPLUS


CN Iridium, tris[(5-methyl-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895556-05-5 CAPLUS


CN Iridium, tris[[5-(1,1-dimethylethyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-

yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-06-6 CAPLUS

CN Iridium, tris[[5-(1-methylethyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-07-7 CAPLUS

CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[4-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-08-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[4-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-09-9 CAPLUS

CN Iridium, tris[(5-fluoro-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-10-2 CAPLUS

CN Iridium, tris[(5-methoxy-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-11-3 CAPLUS

CN Iridium, tris[(5-phenoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-12-4 CAPLUS

CN Iridium, tris[(5-cyano-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-13-5 CAPLUS

CN Iridium, tris[[5-(methylthio)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-14-6 CAPLUS

CN Iridium, tris[[5-(methoxycarbonyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-15-7 CAPLUS

CN Iridium, tris[[5-(methylsulfonyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-16-8 CAPLUS

Iridium, tris[(6-methyl-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-17-9 CAPLUS

CN Iridium, tris[(6-fluoro-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-18-0 CAPLUS

CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[3-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-19-1 CAPLUS


CN Iridium, tris[[6-(1,1-dimethylethyl)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895556-20-4 CAPLUS
 CN Iridium, tris[(6-*cyano*-1,2-phenylene)(3-phenyl-1*H*-imidazol-1-yl-2(3*H*)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-21-5 CAPLUS
 CN Iridium, tris[(6-*nitro*-1,2-phenylene)(3-phenyl-1*H*-imidazol-1-yl-2(3*H*)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-22-6 CAPLUS

CN Iridium, tris[(6-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-23-7 CAPLUS

CN Iridium, tris[(4-methyl-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-24-8 CAPLUS

CN Iridium, tris[(4-fluoro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-25-9 CAPLUS

CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene) [5-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-26-0 CAPLUS

CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[5-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-27-1 CAPLUS

CN Iridium, tris[(4-cyano-1,2-phenylene)(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-28-2 CAPLUS

CN Iridium, tris[(4-nitro-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-29-3 CAPLUS

CN Iridium, tris[(4-methoxy-1,2-phenylene) (3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-30-6 CAPLUS

CN Iridium, tris[[4-(methylthio)-1,2-phenylene](3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-31-7 CAPLUS


CN Iridium, tris[(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)[4'-(trifluoromethyl)[1,1'-biphenyl]-4,3-diyl]]- (9CI) (CA INDEX NAME)



RN 895556-32-8 CAPLUS
 CN Iridium, tris[(5-nitro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-33-9 CAPLUS
 CN Iridium, tris[(5-methyl-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-34-0 CAPLUS

CN Iridium, tris[[5-(1,1-dimethylethyl)-1,2-phenylene](3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-35-1 CAPLUS

CN Iridium, tris[[5-(1-methylethyl)-1,2-phenylene](3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-36-2 CAPLUS

CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[4-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-37-3 CAPLUS

CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[4-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-38-4 CAPLUS

CN Iridium, tris[(5-fluoro-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-39-5 CAPLUS

CN Iridium, tris[(5-methoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-40-8 CAPLUS

CN Iridium, tris[(5-phenoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-41-9 CAPLUS

CN Iridium, tris[(5-cyano-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-42-0 CAPLUS

CN Iridium, tris[[5-(methylthio)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-43-1 CAPLUS

CN Iridium, tris[[5-(methoxycarbonyl)-1,2-phenylene] (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-44-2 CAPLUS

CN Iridium, tris[[5-(methanesulfonyl)-1,2-phenylene](3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-45-3 CAPLUS

CN Iridium, tris[(6-methyl-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895556-46-4 CAPLUS

CN Iridium, tris[(6-fluoro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



IT 895556-47-5 895556-48-6 895556-49-7
 895556-50-0 895556-51-1 895556-52-2
 895556-53-3 895556-54-4 895556-55-5
 895556-56-6 895556-57-7 895556-58-8
 895556-59-9 895556-60-2 895563-91-4
 895563-92-5 895563-93-6 895563-94-7
 895563-95-8 895563-96-9 895563-97-0
 895563-98-1 895563-99-2 895564-00-8
 895564-01-9 895564-02-0 895564-03-1
 895564-04-2 895564-05-3 895564-06-4
 895564-07-5 895564-08-6 895564-09-7
 895564-10-0 895564-11-1 895564-12-2
 895564-13-3 895564-14-4 895564-15-5
 895564-17-7 895564-18-8 895564-19-9
 895564-21-3 895564-22-4 895564-23-5
 895564-24-6 895564-25-7 895564-26-8
 895564-27-9 895564-28-0 895564-29-1


895564-30-4 895564-31-5 895564-32-6
 895564-33-7 895564-34-8 895564-35-9
 895564-36-0 895564-37-1 895564-38-2
 895564-39-3 895564-40-6 895564-41-7
 895564-42-8 895564-43-9 895564-44-0
 895564-45-1 895564-46-2 895564-47-3
 895564-48-4 895564-49-5 895564-50-8
 895564-51-9 895564-52-0 895564-53-1
 895564-54-2 895564-55-3 895564-56-4
 895564-57-5 895564-58-6 895564-59-7
 895564-60-0 895564-61-1 895564-62-2
 895564-63-3 895564-64-4 895564-65-5
 895564-66-6 895564-67-7 895564-68-8
 895564-69-9 895564-70-2 895564-71-3
 895564-72-4 895564-73-5 895564-74-6
 895564-75-7 895564-77-9 895564-78-0
 895564-79-1 895564-80-4 895564-81-5
 895564-82-6 895564-83-7 895564-84-8
 895564-85-9 895564-86-0 895564-87-1
 895564-88-2 895564-89-3 895564-90-6
 895564-91-7 895564-92-8 895564-93-9
 895564-94-0 895564-95-1 895564-96-2
 895564-97-3 895564-98-4 895564-99-5
 895565-00-1 895565-01-2 895565-02-3
 895565-03-4 895565-04-5 895565-05-6
 895565-06-7 895565-07-8 895565-08-9
 895565-09-0 895565-10-3 895565-11-4
 895565-12-5 895565-13-6 895565-14-7
 895565-15-8 895565-16-9 895565-17-0
 895565-18-1 895565-19-2 895565-20-5
 895565-21-6 895565-22-7 895565-23-8
 895565-24-9 895565-25-0 895565-26-1
 895565-27-2 895565-28-3 895565-29-4
 895565-30-7

RL: DEV (Device component use); USES (Uses)


(metal complexes with nucleophilic carbene ligands and devices and processes using them)

RN 895565-47-5 CAPLUS


CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[3-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)



RN 895556-48-6 CAPLUS
 CN Iridium, tris[[6-(1,1-dimethylethyl)-1,2-phenylene](3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-49-7 CAPLUS
 CN Iridium, tris[(6-cyano-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-50-0 CAPLUS

CN Iridium, tris[(6-nitro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-51-1 CAPLUS

CN Iridium, tris[(6-methoxy-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-52-2 CAPLUS

CN Iridium, tris[(4-methyl-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-53-3 CAPLUS

CN Iridium, tris[(4-fluoro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-54-4 CAPLUS

CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[5-(trifluoromethyl)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-55-5 CAPLUS

CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[5-(trifluoromethoxy)-1,2-phenylene]]- (9CI) (CA INDEX NAME)




RN 895556-56-6 CAPLUS

CN Iridium, tris[(4-cyano-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-57-7 CAPLUS

CN Iridium, tris[(4-nitro-1,2-phenylene) (3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-58-8 CAPLUS

CN Iridium, tris[(4-methoxy-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-59-9 CAPLUS

CN Iridium, tris[(4-(methylthio)-1,2-phenylene)(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895556-60-2 CAPLUS

CN Iridium, tris[(3-phenyl-1-imidazolidinyl-2-ylidene)[4'-(trifluoromethyl)[1,1'-biphenyl]-4,3-diyl]]- (9CI) (CA INDEX NAME)




RN 895563-91-4 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895563-92-5 CAPLUS

CN Platinum, [5-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895563-93-6 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]bis[4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC]- (9CI) (CA INDEX NAME)




RN 895563-94-7 CAPLUS

CN Platinum, [5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895563-95-8 CAPLUS

CN Platinum, [5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895563-96-9 CAPLUS

CN Platinum, [5-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895563-97-0 CAPLUS

CN Platinum, [5-methoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895563-98-1 CAPLUS

CN Platinum, [5-phenoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895563-99-2 CAPLUS

CN Platinum, [5-hydroxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-00-8 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-5-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-01-9 CAPLUS

CN Platinum, [5-[(1,1-dimethylethyl)dimethylsilyloxy]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-02-0 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-5-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-03-1 CAPLUS

CN Platinum, [5-(methylthio)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-04-2 CAPLUS

CN Platinum, [5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-05-3 CAPLUS

CN Platinum, [5-(methylsulfinyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-06-4 CAPLUS

CN Platinum, [5-mercapto-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-07-5 CAPLUS

CN Platinum, [5-nitro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-08-6 CAPLUS

CN Platinum, [5-(dimethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-09-7 CAPLUS

CN Platinum, [5-amino-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-10-0 CAPLUS

CN Platinum, [5-(acetylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-11-1 CAPLUS

CN Platinum, [5-[(methylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-12-2 CAPLUS

CN Platinum, [5-(ethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-13-3 CAPLUS

CN Platinum, [5-formyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-14-4 CAPLUS

CN Platinum, [5-(hydroxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-15-5 CAPLUS

CN Platinum, [5-(bromomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-17-7 CAPLUS

CN Platinum, [5-(cyanomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-18-8 CAPLUS

CN Platinate(1-), [5-(carboxylatomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]-, hydrogen (9CI) (CA INDEX NAME)




RN 895564-19-9 CAPLUS

CN Platinum, [5-(methoxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-21-3 CAPLUS

CN Platinum, [5-[(diethylamino)methyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-22-4 CAPLUS

CN Platinum, [5-(3-methoxy-3-oxo-1-propenyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-23-5 CAPLUS

CN Platinum, [5-(3-methoxy-3-oxopropyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-24-6 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-4-(2-pyridinyl-κN)[1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-25-7 CAPLUS


CN Platinum, [2-methyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-26-8 CAPLUS
 CN Platinum, [4-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-27-9 CAPLUS
 CN Platinum, [2-ethenyl-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-28-0 CAPLUS

CN Platinum, [4-ethenyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-29-1 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][3-(2-pyridinyl-κN)[1,1'-biphenyl]-2-yl-κC]- (9CI) (CA INDEX NAME)




RN 895564-30-4 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC]- (9CI) (CA INDEX NAME)




RN 895564-31-5 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-3-(2-pyridinyl-κN)[1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-34-8 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-35-9 CAPLUS


CN Platinum, [4-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-36-0 CAPLUS
 CN Platinum, [2-fluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-37-1 CAPLUS
 CN Platinum, [2,4-difluoro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-38-2 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-6-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-39-3 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-4-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-40-6 CAPLUS

CN Platinum, [4-nitro-2-(2-pyridinyl-κN)-6-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)



RN 895564-41-7 CAPLUS


CN Platinum, [2-nitro-6-(2-pyridinyl-κN)-4-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-42-8 CAPLUS

CN Platinum, [4-cyano-2-(2-pyridinyl-κN)phenyl-κC] [1,2-


phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-43-9 CAPLUS
CN Platinum, [2-cyano-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-44-0 CAPLUS
CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-6-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-45-1 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(2-pyridinyl-κN)-4-(trimethylsilyl)phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895564-46-2 CAPLUS


CN Platinum, [2-cyano-4-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-47-3 CAPLUS

CN Platinum, [4-cyano-2-nitro-6-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895564-48-4 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-[6-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895564-49-5 CAPLUS
 CN Platinum, [2-(6-chloro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895564-50-8 CAPLUS
CN Platinum, [2-(6-nitro-2-pyridinyl-κN)phenyl-κC] [1,2-

phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895564-51-9 CAPLUS
CN Platinum, [2-(6-cyano-2-pyridinyl-κN)phenyl-κC] [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895564-52-0 CAPLUS
 CN Platinum, [2-(6-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895564-53-1 CAPLUS
 CN Platinum, [2-(6-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 895564-54-2 CAPLUS
CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)] [2-(6-

phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 895564-55-3 CAPLUS

CN Platinum, [2-(6-fluoro-2-pyridinyl-κN)phenyl-κC] [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 895564-56-4 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-[3-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-57-5 CAPLUS


CN Platinum, [2-(3-cyano-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-58-6 CAPLUS
 CN Platinum, [2-(3-nitro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-59-7 CAPLUS
 CN Platinum, [2-(3-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-60-0 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(3-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-61-1 CAPLUS


CN Platinum, [2-(3-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-62-2 CAPLUS
 CN Platinum, [2-(3-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-63-3 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-[4-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895564-64-4 CAPLUS
 CN Platinum, [2-(4-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-65-5 CAPLUS
 CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(5-(trifluoromethyl)-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-66-6 CAPLUS

CN Platinum, [2-(5-methyl-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-67-7 CAPLUS

CN Platinum, [2-(5-fluoro-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-68-8 CAPLUS

CN Platinum, [2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-69-9 CAPLUS

CN Platinum, [2-[4-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-70-2 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(5-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-71-3 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)][2-(4-phenyl-2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895564-72-4 CAPLUS

CN Platinum, [3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-73-5 CAPLUS

CN Platinum, [5-fluoro-2-[5-(trifluoromethyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-74-6 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-75-7 CAPLUS


CN Platinum, [4-(dimethyl(tridecafluorohexyl)silyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-77-9 CAPLUS
 CN Platinum, [5-fluoro-2-[5-(pentafluorophenyl)-2-pyridinyl-κN]phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895564-78-0 CAPLUS
 CN Platinum, [2-[5-(pentafluorophenyl)-2-pyridinyl-κN]-5-(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-79-1 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-3-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-80-4 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-4-[5-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-81-5 CAPLUS

CN Platinum, [2',3',4',5',6'-pentafluoro-3-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-4-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-82-6 CAPLUS


CN Platinum, [2',3',4',5',6'-pentafluoro-4-[4-(pentafluorophenyl)-2-pyridinyl-κN][1,1'-biphenyl]-3-yl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-83-7 CAPLUS
 CN Platinum, [4-cyano-3,5-difluoro-2-(4-methoxy-2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 895564-84-8 CAPLUS
 CN Platinum, [2-(4-methoxy-2-pyridinyl-κN)-3,5-bis(trifluoromethyl)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-85-9 CAPLUS

CN Platinum, [2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-86-0 CAPLUS

CN Platinum, [4-cyano-2-[4-(dimethylamino)-2-pyridinyl-κN]-3,5-difluorophenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-89-3 CAPLUS

CN Platinum, [5-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-90-6 CAPLUS

CN Platinum, [5-methoxy-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-91-7 CAPLUS

CN Platinum, [5-(dimethylamino)-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-92-8 CAPLUS


CN Platinum, [4-methyl-2-(2-quinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-93-9 CAPLUS
 CN Platinum, [4-methoxy-2-(2-quinolinylnyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-94-0 CAPLUS
 CN Platinum, [4-(dimethylamino)-2-(2-quinolinylnyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-95-1 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)-5-methylphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-96-2 CAPLUS

CN Platinum, [2-(1-isoquinolinyl-κN)-5-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895564-97-3 CAPLUS

CN Platinum, [5-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI)
(CA INDEX NAME)




RN 895564-98-4 CAPLUS


CN Platinum, [2-(1-isoquinolinyl-κN)-4-methylphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)



RN 895564-99-5 CAPLUS
 CN Platinum, [2-(1-isoquinolinyl-κN)-4-methoxyphenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-00-1 CAPLUS
 CN Platinum, [4-(dimethylamino)-2-(1-isoquinolinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1H-imidazol-1-yl-2(3H)-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-01-2 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895565-02-3 CAPLUS

CN Platinum, [5-methyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-03-4 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][4-(2-pyridinyl-κN) [1,1'-biphenyl]-3-yl-κC]- (9CI) (CA INDEX NAME)




RN 895565-04-5 CAPLUS

CN Platinum, [5-(1,1-dimethylethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-05-6 CAPLUS

CN Platinum, [5-cyclohexyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-06-7 CAPLUS

CN Platinum, [5-fluoro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-07-8 CAPLUS

CN Platinum, [5-methoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-08-9 CAPLUS

CN Platinum, [5-phenoxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-09-0 CAPLUS

CN Platinum, [5-hydroxy-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-10-3 CAPLUS

CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-5-(trifluoromethoxy)phenyl-κC]- (9CI) (CA INDEX NAME)




RN 895565-11-4 CAPLUS

CN Platinum, [5-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(2-pyridinyl-κN)phenyl-κC[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-12-5 CAPLUS


CN Platinum, [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][2-(2-pyridinyl-κN)-5-(trifluoromethyl)phenyl-κC]- (9CI) (CA INDEX NAME)



RN 895565-13-6 CAPLUS
 CN Platinum, [5-(methylthio)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-14-7 CAPLUS
 CN Platinum, [5-(methylsulfonyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-15-8 CAPLUS

CN Platinum, [5-(methylsulfinyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-16-9 CAPLUS

CN Platinum, [5-mercapto-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-17-0 CAPLUS

CN Platinum, [5-nitro-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-18-1 CAPLUS

CN Platinum, [5-(dimethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-19-2 CAPLUS

CN Platinum, [5-amino-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-20-5 CAPLUS

CN Platinum, [5-(acetylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-21-6 CAPLUS

CN Platinum, [5-[(methylsulfonyl)amino]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-22-7 CAPLUS


CN Platinum, [5-(ethylamino)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895565-23-8 CAPLUS
 CN Platinum, [5-formyl-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-24-9 CAPLUS
 CN Platinum, [5-(hydroxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-25-0 CAPLUS

CN Platinum, [5-(bromomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-26-1 CAPLUS

CN Platinum, [5-(cyanomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-27-2 CAPLUS

CN Platinate(1-), [5-(carboxylatomethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, hydrogen (9CI) (CA INDEX NAME)




RN 895565-28-3 CAPLUS

CN Platinum, [5-(methoxymethyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 895565-29-4 CAPLUS

CN Platinum, [5-[(diethylamino)methyl]-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 895565-30-7 CAPLUS

CN Platinum, [5-(3-methoxy-3-oxo-1-propenyl)-2-(2-pyridinyl-κN)phenyl-κC][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:516024 CAPLUS

DOCUMENT NUMBER: 145:28127

TITLE: Preparation of transition metal N-heterocyclic carbene complexes for use in organic light-emitting diodes (OLEDs)

INVENTOR(S): Egen, Martina; Kahle, Klaus; Bold, Markus; Gessner, Thomas; Lennartz, Christian; Nord, Simon; Schmidt, Hans-Werner; Thelakkat, Mukundan; Baete, Markus; Neuber, Christian; Kowalsky, Wolfgang; Schildknecht, Christian; Johannes, Hans-Hermann

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056418	A2	20060601	WO 2005-EP12529	20051123
WO 2006056418	A3	20070111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004057072	A1	20060601	DE 2004-102004057072	20041125
EP 1819717	A2	20070822	EP 2005-811689	20051123

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

CN 101065389	A	20071031	CN 2005-80040471	20051123
JP 2008521946	T	20080626	JP 2007-541832	20051123
US 20080018221	Al	20080124	US 2007-720291	20070525
KR 2007090953	A	20070906	KR 2007-714428	20070625

PRIORITY APPLN. INFO.: DE 2004-102004057072A 20041125
WO 2005-EP12529 W 20051123

OTHER SOURCE(S): MARPAT 145:28127

AB N-Heterocyclic transition metal carbene complexes having pending cyclometalated (hetero)aromatic moiety, [LmKqM[cyclo-C(N(Q-κC2)CY1)[X(Y3p)CY2]]n] [M = Group VIII, VIIB or VIB metal, preferably M = Ir, Rh Pt; cyclo-C(N(Q-κC2)CY1)[X(Y3p)CY2] = substituted cyclometalated N-heterocyclic carbene ligand, preferably substituted imidazolylidene; Q = optionally substituted (hetero)aromatic ring, preferably substituted ortho-metalated Ph, pyridinyl; X = N, O, S, preferably X = N; p = 1, 0; Y3 = H, alkyl; Y1, Y2 = H, alkyl, alkenyl alkynyl, (hetero)aryl, Y1-Y2 or Y2-Y3 = 5- or 6-membered (hetero)cycle; L = mono- or dianionic acidoligand, optionally bidentate; K = neutral mono- or bidentate ligand; n ≥ 1; n+m+q = oxidation number of the metal M], useful as components for light-emitting diodes (OLEDs), preferably as light-emitting components, were prepared by deprotonation and cyclometalation of the corresponding carbene precursors [cyclo-HC(N(QH)CY1)[X(Y3p)CY2]]X1 (X1 = counteranion, preferably X1 = BF4-, PF6-) and tested as emitting substances in model OLEDs. In an example, complex tris-[1-(4-cyano-1,2-phenylene-κC2)-3-methyl-2-imidazolylidene]iridium (I) was prepared with 79.7% yield by methylation of 56 g of 4-(1H-imidazol-1-yl)benzonitrile by 234.2 g of MeI in 560 mL of THF for 48 h followed by deprotonation and complexation with [Ir(cod)Cl]2 in mol ratio 10:1. In another example, a mixture of 1 and 1,3-phenylene-10,10'-bis(phenothiazin-5,5',5'-tetroxide) was used as light-emitting composition, yielding a emission with a maximum at 466 nm, external

quantum yield of 7.3% and efficiency of 9.9 lm W-1.


IT 888725-36-8

RL: DEV (Device component use); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)

(preparation of transition metal N-heterocyclic carbene cyclometalated complexes as electroluminescent components for organic light-emitting diodes)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1202856 CAPLUS

DOCUMENT NUMBER: 145:513425

TITLE:

AUTHOR(S):

Novel deep-blue emitting phosphorescent emitter
Schildknecht, C.; Ginev, G.; Kammoun, A.; Riedl, T.;
Kowalsky, W.; Johannes, H.-H.; Lennartz, C.; Kahle,
K.; Egen, M.; Gessner, T.; Bold, M.; Nord, S.; Erk, P.
Institut fuer Hochfrequenztechnik, Technische Univ.
Braunschweig, Braunschweig, D-38106, Germany
Proceedings of SPIE-The International Society for
Optical Engineering (2005), 5937(Organic
Light-Emitting Materials and Devices IX),
59370E/1-59370E/9

CORPORATE SOURCE:

SOURCE:

CODEN: PSISDG; ISSN: 0277-786X

PUBLISHER: SPIE-The International Society for Optical Engineering

DOCUMENT TYPE:

LANGUAGE:

Journal

English

AB

Currently, one of the most challenging applications for OLEDs is the full color display. The most energy-efficient way to realize light generation in OLEDs is by using phosphorescent emitters. Green and red emitters have already been demonstrated, but the search for blue emitting organic phosphorescent emitters with good color purity is still ongoing with arduous effort. Here we present our work with a new material developed at BASF which allows phosphorescent emission in the deep-blue spectral range. The emitter has an emission maximum at 400 nm, which gives CIE color coordinates of $x = 0.16$ and $y = 0.06$. An OLED device made with this new material shows a maximum external quantum efficiency of 1.5 %. The OLED was built in a three layer structure, with the emitting zone being a hybrid guest-host system. As host material we used the optically and electronically inert polymer poly-methyl-methacrylate (PMMA). Because of its lack of charge transport abilities we doped the host material with a high concentration of the triplet emitting material, i.e. the emitter itself is also used as charge transport material.

IT

888725-36-8


RL: DEV (Device component use); PEP (Physical, engineering or chemical

process); PRP (Properties); PYP (Physical process); PROC (Process); USES (Uses)

(new material developed at BASF allowing phosphorescent emission in deep-blue spectral range)

RN 888725-36-8 CAPLUS

CN Iridium, tris[(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)-1,2-phenylene]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:182773 CAPLUS

DOCUMENT NUMBER: 142:287586

TITLE: Transition metal complexes comprising carbene ligands serving as emitters for organic light-emitting diodes (OLEDs)

INVENTOR(S): Bold, Markus; Lennartz, Christian; Prinz, Martina; Schmidt, Hans-Werner; Thelakkat, Mukundan; Baete, Markus; Neuber, Christian; Kowalsky, Wolfgang; Schildknecht, Christian; Johannes, Hans-Hermann

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019373	A2	20050303	WO 2004-EP9269	20040818
WO 2005019373	A3	20050519		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

DE 10338550	A1	20050331	DE 2003-10338550	20030819
EP 1658349	A2	20060524	EP 2004-764255	20040818

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1871322	A	20061129	CN 2004-80030649	20040818
JP 2007533774	T	20071122	JP 2006-523602	20040818
KR 2007050859	A	20070516	KR 2006-703352	20060217


PRIORITY APPLN. INFO.:
 DE 2003-10338550 A 20030819
 WO 2004-EP9269 W 20040818

AB The use in organic light-emitting diodes (OLEDs) is described of transition metal complexes described by the general formula (L)m(K)oM(carbene)n (M = Co, Rh, Ir, Nb, Pd, Pt, Fe, Ru, Os, Cr, Mo, W, Mn, Tc, Re, Cu, Ag, or Au; carbene = neutral or singly charged anionic mono- or bi- or tridentate carbene ligands, including bis or tris carbene ligands; L = monodentate or bidentate singly or doubly charged anionic ligands; K = neutral mono or bidentate ligands selected from phosphine, phosphates and their derivs., arsenates and their derivs., phosphates, CO, pyridines, nitriles, and conjugated dienes that can form π complexes with M; n \geq 1, with the caveat that, when n > 1, the carbene ligands may be the same or different; and m \geq 0, with the caveat that, if m > 1, the L ligands may be the same or different; o \geq 0, with the caveat that, if o > 1, the K ligands may be the same or different). Light-emitting layers are described which comprise the carbene ligand-containing compds., and OLEDs are also described which employ the layers, along with devices incorporating the OLEDs. Selected transition metal complexes are also described. The use of the transition metal complexes to color bulk polymers is also described.

IT 847049-63-2P 847049-64-3P 847049-65-4P
 847049-66-5P 847063-08-5P 847063-11-0P
 RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (transition metal complexes comprising carbene ligands serving as emitters for organic light-emitting diodes and compds. and diodes and devices using them)

RN 847049-63-2 CAPLUS


CN Iridium, tris[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI)
 (CA INDEX NAME)




RN 847049-64-3 CAPLUS

CN Iridium, tris[(4'-methyl[1,1'-biphenyl]-3,4-diyl)[3-(4-methylphenyl)-1H-imidazol-1-yl-2(3H)-ylidene]]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847049-65-4 CAPLUS

CN Iridium, tris[[1,1'-biphenyl]-3,4-diyl(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)]-, (OC-6-22)- (9CI) (CA INDEX NAME)




RN 847049-66-5 CAPLUS

CN Iridium, tris[[1,1'-biphenyl]-3,4-diyl(3-phenyl-1H-naphth[2,3-d]imidazol-1-yl-2(3H)-ylidene)]-, (9CI) (CA INDEX NAME)




RN 847063-08-5 CAPLUS

CN Iridium, tris[[1,1'-biphenyl]-3,4-diyl(3-phenyl-1H-benzimidazol-1-yl-2(3H)-ylidene)]-, (OC-6-21)- (9CI) (CA INDEX NAME)



RN 847063-11-0 CAPLUS

CN Iridium, tris[[1,1'-biphenyl]-3,4-diyl(3-phenyl-1H-naphth[2,3-d]imidazol-1-yl-2(3H)-ylidene)]-, (OC-6-22)- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:403058 CAPLUS

DOCUMENT NUMBER: 140:406957

TITLE: Preparation of N-heterocyclic carbene complexes as

Dioumaev, Vladimir K.; Bullock, R. Morris

PATENT ASSIGNEE(S): Brookhaven Science Associates, LLC, USA

SOURCE: U.S., 14 pp.

DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6737531	B1	20040518	US 2002-320954	20021217
US 20050075504	A1	20050407	US 2003-731378	20031209
US 7005525	B2	20060228		

PRIORITY APPLN. INFO.: US 2002-320954 A2 20021217
 OTHER SOURCE(S): CASREACT 140:406957; MARPAT 140:406957

AB The preparation of organometallic complex, $[\text{CpM}(\text{CO})_2(\text{NHC})\text{Lk}]^+\text{A}^-$ (M = Mo, W; Cp = (un)substituted cyclopentadienyl radical represented by $[\text{C5Q1Q2Q3Q4Q5}]$, Q1-Q5 = independently selected from the group consisting of H, C1-20 hydrocarbyl, substituted hydrocarbyl, halo, halo-substituted hydrocarbyl, -OR, -C(O)R', -CO₂R', -SiR'₃, and -NR'R'', wherein R', R'' = independently selected from the group consisting of H, C1-20 hydrocarbyl, halo, and halo-substituted hydrocarbyl, wherein Q1-Q5 radicals are optionally linked to each other to form a stable bridging group; NHC = N-heterocyclic carbene; L = neutral electron donor ligand; k = 0-1, or L is an anionic ligand wherein k is 2, and A⁻ is an anion) is described. Thus, reaction of $\text{CpW}(\text{CO})_2(\text{PMe}_3)\text{H}$ with 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (IMes) in PhMe gave 76% $\text{CpW}(\text{CO})_2(\text{IMes})\text{H}$ which on treatment with $\text{Ph}_3\text{C}^+\text{B}(\text{C}_6\text{F}_5)_4^-$ in PhMe gave 91% title catalyst, $[\text{CpW}(\text{CO})_2(\text{IMes})][\text{B}(\text{C}_6\text{F}_5)_4]^-$. Processes using the organometallic complex as catalyst for hydrogenation of aldehydes and ketones are provided. Processes using the organometallic complex as catalyst for the hydrosilylation of aldehydes, ketones and esters are also provided.


IT 688785-27-5P
 RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of nitrogen heterocyclic carbene molybdenum and tungsten complexes as catalysts for hydrogenation and hydrosilylation)

RN 688785-27-5 CAPLUS

CN Tungsten(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl)(η^3 -1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene)-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 646512-81-4
 CMF C28 H29 N2 O2 W
 CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS



IT 688785-26-4P 688785-29-7P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);
 USES (Uses)

(preparation of nitrogen heterocyclic carbene molybdenum and tungsten
 complexes as catalysts for hydrogenation and hydrosilylation)

RN 688785-26-4 CAPLUS

CN Molybdenum(1+), dicarbonyl(η⁵-2,4-cyclopentadien-1-yl) [η³-1,3-
 dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene]-,


stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 646512-79-0

CMF C28 H29 Mo N2 O2

CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS




RN 688785-29-7 CAPLUS
 CN Tungsten(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl) [η^3 -1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene] (tetrahydro-d4-furan-d4)-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI)
 (CA INDEX NAME)

CM 1

CRN 646512-85-8
 CMF C32 H29 D8 N2 O3 W
 CCI CCS

PAGE 1-A




PAGE 2-A



CM 2

CRN 47855-94-7
 CMF C24 B F20
 CCI CCS



IT 688785-28-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of nitrogen heterocyclic carbene molybdenum and tungsten complexes as catalysts for hydrogenation and hydrosilylation)

RN 688785-28-6 CAPLUS


CN Molybdenum(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl) [η^3 -1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene] (tetrahydro-d4-furan-d4)-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 646512-83-6

CMF C32 H29 D8 Mo N2 O3

CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:496788 CAPLUS

DOCUMENT NUMBER: 140:111479

TITLE: An N-heterocyclic carbene as a bidentate hemilabile ligand: a synchrotron X-ray diffraction and density functional theory study

AUTHOR(S): Dioumaev, Vladimir K.; Szalda, David J.; Hanson,

Jonathan; Franz, James A.; Bullock, R. Morris

CORPORATE SOURCE: Chemistry Department, Brookhaven National Laboratory, Upton, NY, 11973-5000, USA

SOURCE: Chemical Communications (Cambridge, United Kingdom) (2003), (14), 1670-1671

CODEN: CHCOFS; ISSN: 1359-7345

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:111479

AB The N-heterocyclic carbene ligand IMes (IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene) was shown by synchrotron crystallog. and DFT computations to adopt a hemilabile bidentate coordination mode in CpM(CO)2(IMes)+B(C6F5)-4 (M = Mo (1), W(2)), with a C:C bond of one mesityl weakly coordinated to the metal. Both 1 and 2 exhibit modest catalytic activity for the hydrogenation of ethanone.

IT 688785-26-4P

RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(W-arene η^2 hapticity; synthesis, bonding and DFT study of 16e- complexes of Mo and W having bidentate hemilabile ligands)

RN 688785-26-4 CAPLUS


CN Molybdenum(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl)[η^3 -1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene]-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 646512-79-0

CMF C28 H29 Mo N2 O2

CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS



IT 688785-27-5P

RL: CAT (Catalyst use); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (crystal structure, W-arene η^2 -hapticity; synthesis, bonding and DFT study of 16e- complexes of Mo and W having bidentate hemilabile ligands)

RN 688785-27-5 CAPLUS


CN Tungsten(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl)[η^3 -1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene]-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 646512-81-4

CMF C28 H29 N2 O2 W

CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS



IT 688785-28-6P 688785-29-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis, bonding and DFT study of 16e- complexes of Mo and W having
 bidentate hemilabile ligands)

RN 688785-28-6 CAPLUS

CN Molybdenum(1+), dicarbonyl(η^5 -2,4-cyclopentadien-1-yl)[η^3 -1,3-
 dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene](tetrahydro-
 d4-furan-d4)-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI)


(CA INDEX NAME)

CM 1

CRN 646512-83-6

CMF C32 H29 D8 Mo N2 O3

CCI CCS




CM 2

CRN 47855-94-7

CMF C24 B F20

CCI CCS




RN 688785-29-7 CAPLUS
 CN Tungsten(1+), dicarbonyl(η5-2,4-cyclopentadien-1-yl)[η3-1,3-dihydro-1,3-bis(2,4,6-trimethylphenyl)-2H-imidazol-2-ylidene](tetrahydro-d4-furan-d4)-, stereoisomer, tetrakis(pentafluorophenyl)borate(1-) (9CI)
 (CA INDEX NAME)

CM 1

CRN 646512-85-8
 CMF C32 H29 D8 N2 O3 W
 CCI CCS

PAGE 1-A




PAGE 2-A



CM 2

CRN 47855-94-7
 CMF C24 B F20
 CCI CCS



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:272293 CAPLUS

DOCUMENT NUMBER: 137:20464

TITLE: C-C and C-H Bond Activation Reactions in

N-Heterocyclic Carbene Complexes of Ruthenium

Jazzar, Rodolphe F. R.; Macgregor, Stuart A.; Mahon,

Mary F.; Richards, Stephen P.; Whittlesey, Michael K.

CORPORATE SOURCE: Department of Chemistry, University of Bath, Bath, BA2

SOURCE: 7AY, UK

Journal of the American Chemical Society (2002),

124(18), 4944-4945

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:20464


AB Thermolysis of Ru(PPh3)3(CO)H2 with the N-heterocyclic carbene bis(1,3-(2,4,6-trimethylphenyl)imidazol-2-ylidene) (IMes) results in C-C activation of an Ar-CH3 bond in one of the mesityl rings of the carbene ligand. Upon addition of IMes to Ru(PPh3)3(CO)H2 at room temperature in the presence of an alkene, C-H bond activation is observed instead. The thermodyn. of these C-C and C-H cleavage reactions have been probed using d. functional theory.

IT 434318-96-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)

RN 434318-96-4 CAPLUS

CN Ruthenium, carbonyl[(3,5-dimethyl-1,2-phenylene)[3-(2,4,6-trimethylphenyl)-1H-imidazol-1-yl-2-(3H)-ylidene]]hydrobis(triphenylphosphine)-, (OC-6-14)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:169514 CAPLUS

DOCUMENT NUMBER: 112:169514

ORIGINAL REFERENCE NO.: 112:28431a,28434a

TITLE: Crystal and molecular structure of the ruthenium-carbene-tetrahydroborate complex [Ru(BH4)(LAr)(PPh3)2]; (LAr = CN(C6H4Me-4)CH2CH2NC6H3Me-4)

AUTHOR(S): Thomas, S. A.

CORPORATE SOURCE: Dep. Chem., Ahmadu Bello Univ., Zaria, Nigeria

SOURCE: Journal of Crystallographic and Spectroscopic Research (1989), 19(6), 1017-31
CODEN: JCREDB; ISSN: 0277-8068

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The title compound is monoclinic, space group P21/c, with a 15.940(1), b 23.357(2), c 18.767(2) Å, and β 132.62(1)°; dc = 1.150 for Z = 4. The final R = 0.074 and Rw = 0.085 for 1848 reflections. Atomic coordinates are given. The BH4- ligand in the complex is bidentate. The lengths of the Ru-carbene C bond and other bonds to the Ru are determined by a combination of several factors, and not just by a purely σ - or π -bonding interaction.

IT 126155-76-8

RL: PRP (Properties)
(crystal structure of)

RN 126155-76-8 CAPLUS

CN Ruthenium, [(5-methyl-1,2-phenylene) [3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]] [tetrahydroborato(1-)-H,H'] bis(triphenylphosphine)-, (OC-6-14)-(9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1983:89623 CAPLUS

DOCUMENT NUMBER: 98:89623

ORIGINAL REFERENCE NO.: 98:13690h,13691a

TITLE: Homoleptic tris(organochelate)iridium(III) complexes
by spontaneous ortho-metalation of electron-rich
olefin-derived N,N'-diarylcarbene ligands and the
x-ray structures of

AUTHOR(S): tris(ortho-metalated-carbene)iridium(III) complexes
Hitchcock, Peter B.; Lappert, Michael F.; Terreros,
Pilar

CORPORATE SOURCE: Sch. Chem. Mol. Sci., Univ. Sussex, Brighton, BN1 9QJ,
UK

SOURCE: Journal of Organometallic Chemistry (1982), 239(2), C26-C30

CODEN: JORCAI; ISSN: 0022-328X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Treating $\{[\text{Ir}(\text{COD})(\mu\text{-Cl})]\}$ with excess of the electron-rich olefin I ($\text{R} = \text{C}_6\text{H}_4\text{Me-p}$, $\text{C}_6\text{H}_4\text{OMe-p}$) affords the ortho-metalated tricyclic II ($\text{R}_1 = \text{Me}$, OMe). II ($\text{R}_1 = \text{Me}$) with HCl yields III; x-ray data show that in III there is an unexpectedly close $\text{Ir}\cdots\text{C}(\text{o-aryl})$ contact involving the free ligand.


IT 84667-30-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and structure of)


RN 84667-30-1 CAPLUS

CN Iridium(1+), [1,3-bis(4-methylphenyl)-2-imidazolidinylidene]bis[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]-, chloride, (SP-5-33)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 84667-32-3P 84668-52-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 84667-32-3 CAPLUS

CN Iridium(1+), [1,3-bis(4-methylphenyl)-2-imidazolidinylidene]bis[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]-, (SP-5-33)-, tetraphenylborate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 84667-31-2
 CMF C51 H52 Ir N6
 CCI CCS


PAGE 1-A



PAGE 2-A




CM 2
 CRN 4358-26-3
 CMF C24 H20 B
 CCI CCS



RN 84668-52-0 CAPLUS
 CN Iridium, tris[(5-methoxy-1,2-phenylene)[3-(4-methoxyphenyl)-1-imidazolidinyl-2-ylidene]]-, (OC-6-22)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



IT 84668-51-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, crystal structure, and protonation of)
 RN 84668-51-9 CAPLUS
 CN Iridium, tris[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]-, (OC-6-22)- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1981:604131 CAPLUS
 DOCUMENT NUMBER: 95:204131
 ORIGINAL REFERENCE NO.: 95:34117a,34120a
 TITLE: Preparation and characterization of new
 cycloplatinated carbene complexes
 AUTHOR(S): Hiraki, Katsuma; Onishi, Masayoshi; Ohnuma, Kohji;
 Sugino, Keiichi
 CORPORATE SOURCE: Fac. Eng., Nagasaki Univ., Nagasaki, 852, Japan
 SOURCE: Journal of Organometallic Chemistry (1981), 216(3),
 413-19
 CODEN: JORCAI; ISSN: 0022-328X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Reaction of $(\text{PtI}(\text{Me})_3)_4$ with bis(1,3-diphenyl-2-imidazolidinylidene) $[(\text{Hdpim})_2]$ gave a new dinuclear carbene complex, $[(\text{Pt}(\text{dpim})\text{I})_2]$ (I) in 84% yields, which contains a cycloplatinated carbene structure. Some mononuclear derivs., $[\text{Pt}(\text{dpim})(\text{acac})]$ (acac = acetylacetonato), $[\text{Pt}(\text{dpim})\text{I}\{\text{P}(\text{OCHMe}_2)_3\}]$, $[\text{Pt}(\text{dpim})(\text{NCMe}_2)_2]\text{ClO}_4$, and $[\text{Pt}(\text{dpim})(\text{COD})]\text{ClO}_4$ (COD = 1,5-cyclooctadiene) were prepared from I. An intermediate species, $[(\text{PtMeI}(\text{Hdpim}))_2]$, leading to I is discussed.

IT 79670-64-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)

RN 79670-64-7 CAPLUS

CN Platinum, di- μ -iodobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)




IT 79670-65-8P 79670-66-9P 79670-68-1P

79766-83-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 79670-65-8 CAPLUS

CN Platinum, (2,4-pentanedionato-O,O') [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)- (9CI) (CA INDEX NAME)



RN 79670-66-9 CAPLUS

CN Platinum, iodo[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][tris(1-methylethyl phosphite-P)]- (9CI) (CA INDEX NAME)



RN 79670-68-1 CAPLUS


CN Platinum(1+), bis(acetonitrile)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 79670-67-0

CMF C19 H19 N4 Pt

CCI CCS




CM 2

CRN 14797-73-0
CMF Cl O4



RN 79766-83-9 CAPLUS
CN Platinum(1+), [(1,2,5,6-η)-1,5-cyclooctadiene][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, perchlorate (9CI) (CA INDEX NAME)
CM 1
CRN 79766-82-8
CMF C23 H25 N2 Pt
CCI CCS



CM 2
CRN 14797-73-0
CMF Cl O4



L4 ANSWER 41 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:65820 CAPLUS

DOCUMENT NUMBER: 94:65820

ORIGINAL REFERENCE NO.: 94:10741a,10744a


TITLE: Cationic (carbene)organopalladium(II) complexes coordinated with cyclic diolefin or organic nitrile
Hiraki, Katsuma; Sugino, Keiichi
Dep. Ind. Chem., Fac. Eng., Nagasaki, 852, Japan
Journal of Organometallic Chemistry (1980), 201(2), 469-75

CODEN: JORCAI; ISSN: 0022-328X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The title compds. I (L2 = norbornadiene, 1,5-cyclooctadiene, dicyclopentadiene; L = CH₂:CHCN, MeCN, p-MeC₆H₄CN) were prepared in 22-59% yields by treating II with AgClO₄ and L2 or L.


IT 70882-99-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation and reaction with olefins and with nitriles)

RN 70882-99-4 CAPLUS

CN Palladium, di-μ-chlorobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)



IT 76375-36-5P 76375-38-7P 76375-40-1P
 76375-42-3P 76375-44-5P 76428-98-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 76375-36-5 CAPLUS
 CN Palladium(1+), [(2,3,5,6-η)-bicyclo[2.2.1]hepta-2,5-diene][1,2-
 phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, perchlorate (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 76375-35-4
 CMF C22 H21 N2 Pd
 CCI CCS



CM 2

CRN 14797-73-0

CMF Cl O4



RN 76375-38-7 CAPLUS


CN Palladium(1+), [(1,2,5,6- η)-1,5-cyclooctadiene][1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 76375-37-6

CMF C23 H25 N2 Pd

CCI CCS



CM 2

CRN 14797-73-0

CMF Cl O4



RN 76375-40-1 CAPLUS


CN Palladium(1+), [(1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene))bis(2-propenenitrile)-, (SP-4-3)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 76375-39-8

CMF C21 H19 N4 Pd

CCI CCS



CM 2

CRN 14797-73-0

CMF C1 O4



RN 76375-42-3 CAPLUS


CN Palladium(1+), bis(acetonitrile)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 76375-41-2

CMF C19 H19 N4 Pd

CCI CCS



CM 2

CRN 14797-73-0


CMF C1 O4



RN 76375-44-5 CAPLUS
 CN Palladium(1+), bis(4-methylbenzonitrile)[1,2-phenylenebis(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 76375-43-4
 CMF C31 H27 N4 Pd
 CCI CCS



CM 2

CRN 14797-73-0
 CMF C1 O4




RN 76428-98-3 CAPLUS
 CN Palladium(1+), [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][(2,3,5,6-η)-3a,4,7,7a-tetrahydro-4,7-methano-1H-indene]-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 76428-97-2

CMF C25 H25 N2 Pd
CCI CCS



CM 2
CRN 14797-73-0
CMF C1 O4



L4 ANSWER 42 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:620917 CAPLUS

DOCUMENT NUMBER: 93:220917

ORIGINAL REFERENCE NO.: 93:35279a,35282a

TITLE: Reactions of halo-bridged organopalladium(II) complexes with an electron-rich olefin. New cyclopalladated carbene complexes and (carbene)chloropalladium(II) complexes containing a σ, π -methallyl group of a π -coordinated-chelating alkyl-palladium σ -bond

AUTHOR(S): Hiraki, Katsuma; Sugino, Keiichi; Onishi, Masayoshi
CORPORATE SOURCE: Fac. Eng., Nagasaki Univ., Nagasaki, 852, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1980), 53(7), 1976-81

CODEN: BCSJA8; ISSN: 0009-2673


DOCUMENT TYPE: Journal

LANGUAGE: English


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Pd(II) complex (I) reacted with the electron-rich olefin
bis(1,3-diphenyl-2-imidazolidinylidene) (L2) to give the new dinuclear
carbene complex (II). Treating I with Tl acetylacetonate, (Me₂CHO)₃P,
4-picoline, AgOAc and L2 gave new carbene complexes (e.g., III). Reaction
of IV and V with L2 gave carbene complexes VI and VII, resp.
- IT 70882-99-4P 70883-00-0P 70883-01-1P
70883-02-2P 70883-03-3P 70883-04-4P
75551-63-2P 75551-65-4P 75551-66-5P
75559-72-7P 75598-36-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
- RN 70882-99-4 CAPLUS
- CN Palladium, di-μ-chlorobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)




- RN 70883-00-0 CAPLUS
- CN Palladium, (2,4-pentanedionato-0,0') [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)- (9CI) (CA INDEX NAME)




- RN 70883-01-1 CAPLUS
- CN Palladium, chloro(4-methylpyridine) [1,2-phenylene(3-phenyl-1-

imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 70883-02-2 CAPLUS

CN Palladium, chloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][tris(1-methylethyl phosphite-P)-, (SP-4-4)- (9CI) (CA INDEX NAME)




RN 70883-03-3 CAPLUS


CN Palladium, bis[μ-[acetato-O:O']bis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)



RN 70883-04-4 CAPLUS
 CN Palladium, di- μ -bromobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)




RN 75551-63-2 CAPLUS
 CN Palladium, bromo(4-methylpyridine)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)



RN 75551-65-4 CAPLUS
 CN Palladium(1+), (1,3-diphenyl-2-imidazolidinylidene)(4-methylpyridine)(1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene))-, (SP-4-2)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 75551-64-3
 CMF C36 H34 N5 Pd
 CCI CCS




CM 2

CRN 14797-73-0
 CMF Cl O4




RN 75551-66-5 CAPLUS

CN Palladium, bromo(1,3-diphenyl-2-imidazolidinylidene)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-4)- (9CI) (CA INDEX NAME)



RN 75559-72-7 CAPLUS

CN Palladium, chloro(1,3-diphenyl-2-imidazolidinylidene)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-4)- (9CI) (CA INDEX NAME)



RN 75598-36-6 CAPLUS


CN Palladium(1+), (1,3-diphenyl-2-imidazolidinylidene)(4-ethylpyridine)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-4)-, perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 75598-35-5

CMF C36 H34 N5 Pd

CCI CCS



CM 2

CRN 14797-73-0

CMF C1 O4



L4 ANSWER 43 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:146879 CAPLUS

DOCUMENT NUMBER: 92:146879

ORIGINAL REFERENCE NO.: 92:23877a,23880a


TITLE: Carbene complexes. 16. Synthesis of NN'N''N'''-tetraaryl-substituted electron-rich olefin-derived carbeneruthenium(II) complexes containing an ortho-metalated-N-arylcabene ligand; crystal structures of RuClR(PET3)2 and Ru(CO)ClR(PET3)2 (R = 1,3-bis(4-tolyl)imidazolidin-2-ylidene-C2C2')

AUTHOR(S): Hitchcock, Peter B.; Lappert, Michael F.; Pye, Peter L.; Thomas, Sunday

CORPORATE SOURCE: Sch. Mol. Sci., Univ. Sussex, Brighton, BN1 9QJ, UK
SOURCE: Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1979), (12), 1929-42
CODEN: JCDTBI; ISSN: 0300-9246

DOCUMENT TYPE: Journal
LANGUAGE: English

GI



AB RuCl₂(PPh₃)₃ reacts thermally with the electron-rich olefins I [R = Ph, C₆H₄Me-4 (II), C₆H₄OMe-4 or -2), with elimination of PPh₃ and HCl, to form 5-coordinated III containing an o-metalated N-arylcarbene ligand L (R₁ = H, Me, OMe). The reaction of II with RuCl(NO)(PPh₃)₂ also gives the appropriate RuClL(PPh₃)₂. Complexes III readily undergo phosphine substitution reactions with PR₃ [R₂ = Et₃, Bu₃, Bu₂Ph, Et₂Ph, Me₂Ph, but not tricyclohexyl]. The reaction of III (R = C₆H₄Me-4, R₁ = Me) with I (R = Et) (IV) gives the bis(carbene) complex RuClL(L₁)(PPh₃) (L₁ = nonmetalated carbene ligand derived from IV). Small ligands [e.g., CO, PF₃, P(OMe)₃ or NCM] generally add to form 6-coordinate complexes of variable thermal stability. The reaction of RuCl₃(NO)(PPh₃)₂ with II also gives an o-metalated complex, RuCl₂L(NO)PPh₃. This complex does not undergo substitution by PR₃ but with IV, NOCl is lost to give RuCl(L₁)(PPh₃). The IR and ¹H, ¹³C and ³¹P NMR spectra of the complexes were studied. The 5- and 6-coordinate complexes are stereochem. rigid in solution. The crystal and mol. structures of the title complexes were determined


by x-ray diffraction and refined to R 0.054 and 0.045, resp., for 3035 and 3142 reflections, resp. In the overall pseudooctahedral geometry about Ru, the 2 complexes differ only in the replacement of a weak Ru...HC contact (2.23 Å) in the former for a CO ligand in the latter.

IT 64055-31-8P 72904-25-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal and mol. structure of)


RN 64055-31-8 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triethylphosphine)-, (SP-4-3)- (9CI) (CA INDEX NAME)



RN 72904-25-7 CAPLUS

CN Ruthenium, carbonylchloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triethylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




IT 64055-27-2P 64055-28-3P 72871-21-7P
 72871-22-8P 72871-23-9P 72871-24-0P
 72871-25-1P 72871-26-2P 72871-27-3P
 72871-28-4P 72871-29-5P 72871-30-8P
 72871-31-9P 72871-32-0P 72882-43-0P
 72882-44-1P 72882-45-2P 72882-46-3P
 72904-24-6P 73016-72-5P 73016-73-6P
 73016-74-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 64055-27-2 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene) [3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 64055-28-3 CAPLUS

CN Ruthenium, chloro[(1,3-diethyl-2-imidazolidinylidene) [(5-methyl-1,2-phenylene) [3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]](triphenylphosphine)- (9CI) (CA INDEX NAME)




RN 72871-21-7 CAPLUS

CN Ruthenium, chlorobis(dimethylphenylphosphine)[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 72871-22-8 CAPLUS

CN Ruthenium, carbonylchloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis(triethylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 72871-23-9 CAPLUS

CN Ruthenium, chloro(1,3-diethyl-2-imidazolidinylidene)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)](triphenylphosphine)-, (SP-5-53)- (9CI) (CA INDEX NAME)




RN 72871-24-0 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triethylphosphine)(trimethyl phosphite-P)-, (OC-6-45)- (9CI) (CA INDEX NAME)




RN 72871-25-1 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]](phosphorous trifluoride)bis(triphenylphosphine)-, (OC-6-45)- (9CI) (CA INDEX NAME)




RN 72871-26-2 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]](phosphorous trifluoride)bis(triethylphosphine)-, (OC-6-45)- (9CI) (CA INDEX NAME)




RN 72871-27-3 CAPLUS

CN Ruthenium, (acetoneitrile)chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 72871-28-4 CAPLUS

CN Ruthenium, chloro[1,2-ethanediylbis(diphenylphosphine)-P,P'][(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]](triphenylphosphine)-, (OC-6-43)- (9CI) (CA INDEX NAME)




RN 72871-29-5 CAPLUS

CN Ruthenium, carbonylchloro[(3-methoxy-1,2-phenylene)[3-(2-methoxyphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 72871-30-8 CAPLUS

CN Ruthenium, chloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis(triphenylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 72871-31-9 CAPLUS

CN Ruthenium, chloro[5-methoxy-1,2-phenylene][3-(4-methoxyphenyl)-1-imidazolidinyl-2-ylidene]bis(triphenylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 72871-32-0 CAPLUS

CN Ruthenium, chloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis(triethylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 72882-43-0 CAPLUS

CN Ruthenium, carbonylchloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis(triphenylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 72882-44-1 CAPLUS

CN Ruthenium, carbonylchloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]bis(tributylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 72882-45-2 CAPLUS

CN Ruthenium, chloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]tris(trimethyl phosphite-P)-, (OC-6-34)- (9CI) (CA INDEX NAME)




RN 72882-46-3 CAPLUS

CN Ruthenium, chlorobis(dibutylphenylphosphine)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 72904-24-6 CAPLUS

CN Ruthenium, carbonylchloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (OC-6-42)- (9CI) (CA INDEX NAME)




RN 73016-72-5 CAPLUS

CN Ruthenium, chlorobis(diethylphenylphosphine)[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 73016-73-6 CAPLUS


CN Ruthenium, iodo[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)



RN 73016-74-7 CAPLUS
 CN Ruthenium, dichloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]nitrosyl(triphenylphosphine)-, (OC-6-42)- (9CI)
 (CA INDEX NAME)



L4 ANSWER 44 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1979:474697 CAPLUS
 DOCUMENT NUMBER: 91:74697
 ORIGINAL REFERENCE NO.: 91:12085a,12088a
 TITLE: Synthesis and characterization of new cyclopalladated carbene complexes
 AUTHOR(S): Hiraki, K.; Onishi, M.; Sugino, K.
 CORPORATE SOURCE: Fac. Eng., Nagasaki Univ., Nagasaki, Japan
 SOURCE: Journal of Organometallic Chemistry (1979), 171(3), C50-C52
 CODEN: JORCAI; ISSN: 0022-328X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Treating dipalladium complex I with bis(1,3-diphenyl-2-imidazolidinylidene) gave 46.2% chloro-bridged carbene complex II (R = Cl) having a cyclopalladated chelate structure involving a Pd-carbene and a Pd-aryl bond. Reactions with II (R = Cl) gave II (R = Br, OAc) and III (R1 = Cl, R2 = 4-methylpyridine; R1R2 = acetylacetonato).

IT 70882-99-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of)

RN 70882-99-4 CAPLUS


CN Palladium, di- μ -chlorobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)



IT 70883-00-0P 70883-01-1P 70883-02-2P
 70883-03-3P 70883-04-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 70883-00-0 CAPLUS

CN Palladium, (2,4-pentanedionato-O,O') [1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]-, (SP-4-3)- (9CI) (CA INDEX NAME)




RN 70883-01-1 CAPLUS

CN Palladium, chloro(4-methylpyridine)[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]- (9CI) (CA INDEX NAME)




RN 70883-02-2 CAPLUS

CN Palladium, chloro[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)][tris(1-methylethyl) phosphite-P]-, (SP-4-4)- (9CI) (CA INDEX NAME)




RN 70883-03-3 CAPLUS

CN Palladium, bis[μ-(acetato-O:O')]bis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)



RN 70883-04-4 CAPLUS
 CN Palladium, di- μ -bromobis[1,2-phenylene(3-phenyl-1-imidazolidinyl-2-ylidene)]di- (9CI) (CA INDEX NAME)



L4 ANSWER 45 OF 45 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1977:517948 CAPLUS
 DOCUMENT NUMBER: 87:117948
 ORIGINAL REFERENCE NO.: 87:18737a,18740a
 TITLE: Spontaneous N-aryl (rather than P-aryl) orthometalation in the dichlorotris(triphenylphosphine)ruthenium-bi-1,3-di-p-tolylimidazolidinylidene system; x-ray crystal and molecular structure of a stereochemically rigid 5-coordinate RuII complex, with a short (2.2 Å) Ru....H contact
 AUTHOR(S): Hitchcock, Peter B.; Lappert, Michael F.; Pye, Peter L.
 CORPORATE SOURCE: Sch. Mol. Sci., Univ. Sussex, Brighton, UK
 SOURCE: Journal of the Chemical Society, Chemical

Communications (1977), (7), 196-8

CODEN: JCCCCAT; ISSN: 0022-4936


Journal

English

DOCUMENT TYPE:

LANGUAGE:

GI




AB [RuCl₂(PPh₃)₃] with bi-1,3-di-p-tolylimidazolidinylidene in xylene at 140° gave the complex I (R = Ph). The reaction involves carbene-metal formation accompanied by ortho metalation. I (R = Ph) with PEt₃ gave I (R = Et). X-ray crystallog. anal. of I (R = Et) showed that Ru-Ccarbene [1.908(5) Å] is significantly shorter than Ru-Caryl [1.994(5) Å]. I (R = Et) is stereochem. rigid probably because of the close Ru.tplbond.H contact.

IT 64055-31-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)

RN 64055-31-8 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triethylphosphine)-, (SP-4-3)- (9CI) (CA INDEX NAME)




IT 64055-27-2P 64055-28-3P 64055-29-4P

64055-30-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 64055-27-2 CAPLUS

CN Ruthenium, chloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)-, (SP-5-43)- (9CI) (CA INDEX NAME)




RN 64055-28-3 CAPLUS

CN Ruthenium, chloro(1,3-diethyl-2-imidazolidinylidene)[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]](triphenylphosphine)- (9CI) (CA INDEX NAME)




RN 64055-29-4 CAPLUS

CN Ruthenium, carbonylchloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triphenylphosphine)- (9CI) (CA INDEX NAME)



RN 64055-30-7 CAPLUS

CN Ruthenium, carbonylchloro[(5-methyl-1,2-phenylene)[3-(4-methylphenyl)-1-imidazolidinyl-2-ylidene]]bis(triethylphosphine)- (9CI) (CA INDEX NAME)



=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

255.80	441.90
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-36.90	-36.90
--------	--------

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 19:37:56 ON 16 JUN 2009